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ABSTRACT 
Jeran Kent Stratford: Aberrant gene expression: diagnostic markers and therapeutic targets 
for pancreatic cancer 
(Under the direction of Jen Jen Yeh and Channing J. Der) 
 
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer and the fourth 
leading cause of cancer-related death in the United States. The overall median survival for 
patients diagnosed with PDAC is five to eight months. The poor outcome is due, in part, to a 
lack of disease-specific symptoms that can be used for early detection, and as such, most 
patients present with locally advanced or metastatic disease at the time of diagnosis. 
Therefore, the need for diagnostic tools is both great and urgent. Furthermore, current 
chemotherapies have low response rates and high toxicity, limiting their use, and there are 
currently no effective targeted therapies for PDAC. Therefore, a greater understanding of the 
underlying biology of pancreatic cancer is needed to identify tumor-specific vulnerabilities 
that can be therapeutically exploited.  
Pancreatic cancer development is driven by genomic changes that alter gene 
expression. Aberrant gene expression produces changes in protein expression, which in turn 
may confer growth advantages to the tumor; often the tumor then develops a dependency on 
continued aberrant gene and protein expression. Determining how aberrant genome-wide 
gene expression changes affect the biology of the tumor is of paramount importance in our 
continued efforts to improve patient therapy. By identifying and establishing a role for the 
overexpressed genes in PDAC we can discover new avenues for therapeutic intervention and 
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potentially predict the most effective therapy for each individual and avoid therapies that 
may have little clinical efficacy. My research aimed to identify aberrantly expressed genes in 
primary tumor samples from PDAC patients and characterize the diagnostic and therapeutic 
value of the identified genes. The work outlined in this dissertation focuses first on 
identifying a prognostic signature of genes with the ability to stratify patients into high and 
low risk groups, and second on assessing the biological importance of overexpression of the 
dual-specificity protein kinase TTK for pancreatic cancer oncogenesis. Together these two 
investigations provide a basis for translating molecular changes in tumor biology into 
improved therapy for pancreatic cancer patients.   
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CHAPTER I 
Introduction 
 
  Pancreatic cancer remains one of the most lethal cancers having an overall five-year 
survival rate of less than 5% (Cooper et al., 2013; Wolfgang et al., 2013; Heinemann et al., 
2013). The annual percent change in the number of people diagnosed with pancreatic cancer has 
increased by 0.7% and death rates have been rising by 0.4% each year (http://seer.cancer.gov). 
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States and is 
projected to become the second leading cause of cancer-related death by 2030 (Burris et al., 
1997; Rahib et al., 2014; Siegel et al., 2014).  
  The poor prognosis of pancreatic cancer patients, in part, stems from the silent nature and 
lack of recognizable clinical symptoms, absence of early detection and diagnostic tools, inherent 
aggressiveness and high metastatic potential of the tumor, and resistance to standard 
chemotherapies. Surgical resection followed by adjuvant therapy remains the only potentially 
curative therapy. However, more than 80% of pancreatic cancer patients present with locally 
advanced or metastatic disease at diagnosis and are not considered candidates for surgery (Arnal 
and Wade, 1995; Sohn et al., 2000).   
  Chemotherapy is the standard of care for metastatic or locally advanced pancreatic 
cancer. Gemcitabine, alone or in combination, has been the standard chemotherapeutic agent for 
PDAC for over 15 years (Hoff et al., 2013; Werner et al., 2013). Recently the gemcitabine-free 
FOLFIRINOX protocol has also been approved to treat pancreatic cancer (Conroy et al., 2011). 
Although overall survival is increased for patients treated with chemotherapy, the low response 
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rate, high toxicity, and a lack of sustained efficacy pose significant hurdles to overcome (Oken et 
al., 1982; Maginn et al., 2014). Therefore there is a dire need to develop clinically effective 
strategies. I propose that a better understanding of the fundamental molecular biology of 
pancreatic cancer will allow for development of novel therapeutic approaches and diagnostic 
tools.  
Pancreas anatomy and function 
  The pancreas is the main organ responsible for maintaining glucose homeostasis and 
regulating protein, lipid, and carbohydrate digestion. These functions are carried out by two 
physiologically distinct functional components: endocrine and exocrine pancreas. Endocrine 
pancreas is composed of four specialized cell types that are clustered into structures called the 
Islets of Langerhans (Bardeesy and DePinho, 2002). Islets are found throughout the pancreas and 
regulate metabolism and glucose homeostasis by secretion of hormones including glucagon, 
insulin, and somatostatin into the blood stream produced by alpha, beta, and delta cells 
respectively.  
  Exocrine pancreas accounts for the majority of the tissue mass of the pancreas and is 
responsible for the production and delivery of digestive zymogens into the gastrointestinal tract. 
Exocrine pancreas is composed of acinar and ductal cells that are organized into a branched 
network. The acinar cells synthesize and secrete the zymogens into the ductal lumen to be 
emptied into the small intestine to aid in digestion (Figure 1). 
Pancreatic ductal adenocarcinoma development 
  Pancreatic cancer can arise from the endocrine or the exocrine pancreas components. 
Endocrine tumors arise from cells in the hormone-producing Islets of Langerhans of the pancreas 
and account for less than 5% of the total pancreatic cancer cases (Halfdanarson et al., 2008). 
Exocrine tumors arise from pancreatic acinar or ductal cells and account for 95% of pancreatic  
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Figure 1. Anatomy of the pancreas.  The pancreas is an organ situated behind the stomach and 
adjacent to the duodenum of the small intestine. The widest part of the pancreas is called the 
head, the middle section is referred to as the body, and the thinnest section is named the tail. The 
pancreas is composed of two functionally distinct compartments: endocrine and exocrine 
pancreas. Endocrine pancreas secretes hormones directly into a capillary network and is 
organized into Islets of Langerhans. Exocrine pancreas is composed of acinar cells that produce 
digestive enzymes that are secreted into ducts that feed into the small intestine to aide in 
digestion.  	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Figure 2. Precursor lesions of PDAC. Histopathological images of the normal pancreas 
and the three precursor lesions. Lesions progress towards pancreatic ductal 
adenocarcinoma in a temporal sequence. Increasing dysplasia can be observed during 
progression. Adapted from Hezel AF et al. (2006) Genes Dev. 20:1218-1249. PanIN: 
Pancreatic intraepithelial neoplasm precursor; PDAC: pancreatic ductal adenocarcinoma; 
MCN: mucinous cystic neoplasm; IPMN: intraductal papillary mucinous neoplasm. 	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tumors. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of exocrine 
pancreatic cancer, accounting for more than 90% of total cases of exocrine pancreatic cancers 
(Antoniou et al., 2013). 
  The progression from non-neoplastic cells to a malignant adenocarcinoma occurs 
through a series of precursor lesions characterized by increasing levels of dysplasia (Hezel et 
al., 2006). Three premalignant, non-invasive lesions of PDAC have been identified: 
intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), and 
pancreatic intraepithelial neoplasia (PanIN) (Figure 2). Previous studies have identified 
increasing genomic instability in premalignant and malignant PDAC lesions.  
Staging of pancreatic cancer 
  In 2009 the American Joint Committee on Cancer (AJCC) established an official 
guide for clinical staging of pancreatic cancer. The system is based on the TNM scale. The T 
variable describes the primary tumor size and invasion beyond the pancreas. The N variable 
describes the involvement of regional lymph nodes. The M variable describes the presence or 
absence of distant metastatic lesions (Table 1). Pancreatic cancers are staged from 0-IV; a 
stage 0 exhibits no evidence of a primary tumor and stage IV is any primary tumor with 
distant metastasis regardless of lymph node involvement (Table 2).  
  Pancreatic cancer has few symptoms and no early detection diagnostics. As such, 
over 50% of pancreatic cancers are classified as stage IV at the time of diagnosis (Seer 
cancer statistics review). The five-year survival rate of localized exocrine pancreas cancer 
patients is 26% whereas patients diagnosed with stage IV is 2%, 
(http://seer.cancer.gov/statfacts/html/pancreas.html, Figure 3).  
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Table 1. Pancreatic cancer TNM classification 
T Classification Primary Tumor 
T0 No evidence of primary tumor 
Tis (Carcinoma in situ) N/A 
T1 Tumor limited to the pancreas, ≤2 cm in greatest dimension. 
T2 Tumor limited to the pancreas,  >2 cm in greatest dimension. 
T3 
Tumor extends beyond the pancreas but without involvement of 
the celiac axis or the superior mesenteric artery. 
T4 
Tumor involves the celiac axis or the superior mesenteric artery 
(unresectable primary tumor). 
TX Tumor cannot be assessed 
N Classification Nodal Metastasis 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
NX Regional lymph nodes cannot be assessed 
M Classifications Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
Reproduced from Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging 
Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.  
	   7	  
Table 2. AJCC stage groupings for pancreatic cancer 
Stage T Class N Class M Class Treatment 
0 Tis N0 M0  
IA T1 N0 M0 
Surgery 
Chemotherapy 
Chemoradiation 
IB T2 N0 M0 
IIA T3 N0 M0 
IIB T1 N1 M0 
 T2 N1 M0 
 T3 N1 M0 
III T4 Any N M0 Chemotherapy 
Palliative therapy IV Any T Any N M1 
Reproduced from Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging 
Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.  
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Figure 3. Early detection of pancreatic cancer associated with better 5-year survival. 
Patients with localized (confined to primary site) disease have the highest survival. Most 
patients are diagnosed with regional (regional lymph nodes involved) and distant (metastasis 
present) disease and have a worse prognosis. From SEER 18 2004-2010, all races, both sexes 
by SEER summary stage 2000. 
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Pancreatic ductal adenocarcinoma outcome and treatment 
  Pancreatic cancer is a lethal disease and is the fourth leading cause of cancer-related 
death in the United States (Siegel et al., 2014). The overall median survival for patients 
diagnosed with PDAC is five to eight months. The five-year survival rate for PDAC is less 
than 5% (Bilimoria et al., 2007). The poor outcome of PDAC patients stems from a strong 
tendency for tumors to invade and metastasize, resistance to chemotherapy, and a lack of 
disease-specific signs and symptoms that can be used for early detection. Because the 
symptoms of pancreatic cancer are absent through most of the development of the tumor, 
most patients are diagnosed at an advanced stage of PDAC and often present with tumors 
that have spread beyond the initial site. PDAC often invades through nerves and perineural 
spaces, lymphatic spaces, and small veins leading to metastasis beyond the pancreas (Cleary 
et al., 2004).  
  Surgical resection followed by adjuvant chemotherapy is the only potentially curative 
therapy for PDAC. Patients with localized disease are considered as eligible candidates for 
surgical resection. The location of the tumor defines the surgical procedure. Of total cases, 
20-25% of pancreatic tumors arise in the body or tail of the pancreas.  To resect these tumors, 
a distal pancreatectomy is performed as a transection of the pancreas to the left of the 
superior mesenteric vein/portal vein trunk with possible resection of peripancreatic lymph 
nodes and potentially the spleen. This procedure carries up to a 5.9% mortality rate and a 
45.3% major morbidity with the common causes of morbidity being pancreatic leak, splenic 
vein thrombosis, intra-abdominal abscess, and postoperative bleeding (Cuschieri et al., 1996; 
Lillemoe et al., 1999; Birkmeyer et al., 2002; King et al., 2008; Venkat et al., 2012; Iacono 
et al., 2013). 
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  The majority of PDAC tumors, 60-70%, arise in the head of the pancreas. For PDAC 
located in the pancreas head, a pancreaticoduodenectomy, or Whipple procedure, is the 
procedure of choice. This procedure involves resection of the pancreatic head, duodenum, a 
portion of the jejunum common bile duct, gallbladder, and a partial gastrectomy but may be 
pylorus sparing (Figure 4). The Whipple procedure carries a 4% perioperative mortality rate 
and a 59% major morbidity with common causes of morbidity being infectious 
complications, dehydration, delayed gastric emptying, abscess formation, development of 
fistulas, and abdominal bleeding (Sohn et al., 2000; DeOliveira, Winter, Schafer, 
Cunningham, Cameron, Yeo, and Clavien, 2006a; Yermilov et al., 2008; SA Ahmad et al., 
2012).  
  Although surgical resection of PDAC tumors is quite intensive, there are also 
substantial clinical benefits. Patients who are candidates for resection have an improved 
median overall survival of 23 months with a 15-30% five-year survival rates (Neuhaus et al., 
2008; Paulson et al., 2013; Rahib et al., 2014; Siegel et al., 2014). Balancing the potential 
risks and benefits from surgical resection make the decision about which patients would 
benefit from the procedure quite complicated.  
  PDAC patients who undergo surgery have the best overall survival, but peripancreatic 
lymphatic involvement, peripancreatic nodal involvement, presence of distant metastasis, 
greater than 180-degrees encasement of the superior mesenteric artery or celiac axis, 
unreconstructable superior mesenteric vein/portal vein occlusion, and involvement of inferior 
vena cava or aorta are contraindications to surgical resection and are present in 80% of 
patients at the time of diagnosis (Sohn et al., 2000; Seufferlein et al., 2012). However, a 
classification of stage III borderline resectable disease has recently been defined as abutment 
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Figure 4. The Whipple procedure. Structure of the pancreas and other digestive organs 
before the procedure (left) and after (right) the procedure, with structures to be excised 
shown pink. Adapted from Freelove R and Walling AD. (2006) Am Fam Physician 
73(3):485-492. 
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(less than 180-degree involvement) of the vasculature without any indication of metastatic 
disease (Callery et al., 2009; Werner et al., 2013; Wolfgang et al., 2013). Although surgical 
resection of borderline resectable tumors is considered technically possible, the probability of 
a positive margin is high. Neoadjuvant therapy is recommended to patients with borderline 
resectable tumors in an effort to shrink the tumor in preparation for surgical resection. 
Patients whose tumors are converted from unresectable to resectable disease after 
neoadjuvant therapy and undergo tumor resection have comparable overall survival to 
primarily resectable patients (Conroy et al., 2011; Cooper et al., 2013; Heinemann et al., 
2013). Therefore, a pressing need exists to determine the patients who may respond to 
neoadjuvant therapy as a therapeutic strategy is established for patients with borderline 
resectable disease. 
  For the 80% of patients who are not eligible for surgery, chemotherapy is the standard 
of care. In 1997 gemcitabine (Gemzar) monotherapy was approved for first-line treatment of 
PDAC, having shown to improve overall survival compared to 5-fluorouracil (5-FU, 4.41 
months for 5-FU vs. 5.4 months for gemcitabine) (Burris et al., 1997; Maginn et al., 2014). 
Gemcitabine is a nucleoside analog of cytidine and inhibits DNA synthesis. Many 
combination therapies of cytotoxic drugs with gemcitabine have been conducted but failed to 
provide increased clinical benefit. Recently a combination of gemcitabine and nanoparticle 
albumin-bound paclitaxel (nab-paclitaxel, Abraxane) was shown to have clinical efficacy 
over gemcitabine monotherapy. Paclitaxel is a stabilizing agent that prevents microtubule 
depolymerization to disrupt mitosis (Arnal and Wade, 1995; Bardeesy and DePinho, 2002). 
In a recent phase III clinical trial nab-paclitaxel in combination with gemcitabine improved 
response rate (7% for gemcitabine and 23% in combination), progression-free survival (3.7 
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months for gemcitabine alone vs. 5.5 months in combination), and overall survival (6.7 
months for gemcitabine vs. 8.5 months in combination) (Halfdanarson et al., 2008; Hoff et 
al., 2013). 
  One of the best advancements in the treatment of unresectable PDAC is the 
combination therapy composed of the folic acid derivative leucovorin, 5-fluorouracil, 
topoisomerase I inhibitor irinotecan, and the DNA alkylating agent oxaliplatin, 
(FOLFIRINOX). In a phase III clinical trial FOLFIRINOX had a better response rate than 
gemcitabine alone (32% for FOLFIRINOX compared to 9% for gemcitabine). In addition 
FOLFIRINOX had a significantly higher time of progression-free survival (6.4 months for 
FOLFIRINOX vs. 3.3 months for gemcitabine) as well as overall survival (11.1 months for 
FOLFIRINOX compared to 6.8 months for gemcitabine). Although the clinical benefit of 
FOLFIRINOX is exciting, the use of FOLFIRINOX is limited due to greater toxicity. 
Patients given FOLFIRINOX experienced neutropenia, febrile neutropenia, 
thrombocytopenia, diarrhea, neuropathy, vomiting, and fatigue (Conroy et al., 2011; 
Antoniou et al., 2013). Therefore, FOLFIRINOX is reserved for the healthiest patients as 
defined as an Eastern Cooperative Oncology Group (ECOG) performance status less than 1 
(Oken et al., 1982; Hezel et al., 2006) (Table 3). Studies are currently underway to modify 
the regimen to reduce toxicity and expand the population of patients who can receive this 
therapy. Given the complexity and the heterogeneity of PDAC, gaining a greater insight into 
the clinical characteristics, molecular biology, dependencies, and an understanding of the 
transformation and metastatic process will be required to drive future diagnostic and 
therapeutic developments. 
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Mitotic fidelity of PDAC 
Genomic instability   
  Genomic instability and mutations are hallmarks of cancer (Hanahan and Weinberg, 
2011; Siegel et al., 2014). PDAC has been shown to exhibit characteristics of genomic 
instability including mutations (Bilimoria et al., 2007; S Jones et al., 2008; Biankin et al., 
2012), copy number variations (Harada et al., 2008; Fu et al., 2008), genomic 
rearrangements (PJ Campbell et al., 2010), and microsatellite instability (Brentnall et al., 
1995).  In addition to genetic instability, PDAC cells frequently missegregate their 
chromosomes (Hansel et al., 2003), resulting in cellular aneuploidy, a state where cells have 
a chromosomal number other than 46 (Kops et al., 2005). The process whereby cancer cells 
acquire and propagate chromosomal abnormalities is termed chromosomal instability 
(Gordon et al., 2012).  Three major mechanisms have been proposed whereby cells acquire 
chromosomal instability: mitotic checkpoint defects, centrosome over-duplication, or faulty 
sister chromatid cohesion (Duijf and Benezra, 2013). 
Spindle assembly checkpoint 
  Mitotic checkpoints are important for regulating the proper progression through the 
cell cycle. Deregulation of mitotic entry and progression can lead to cellular transformation. 
Mitotic checkpoints exist throughout the cell cycle to halt mitotic progression until the 
current stage of the cell cycle is completed. Checkpoints remain active until error-free 
completion of the current mitotic process, thus ensuring proper timing and transition between 
stages and ultimately prevent the propagation of transformed cells.  
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Table 3. ECOG Performance Status 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours 
3 Capable of only limited self care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled, Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
 
Reproduced from Oken MM et al., (1982) Am J Clin Oncol 5:649-655.  
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  Of particular interest in regards to chromosomal instability is the spindle assembly 
checkpoint (SAC). Genetic screens in the budding yeast Saccharomyces cerevisiae originally 
identified mutants that failed to arrest in mitosis when the spindle was destroyed leading to 
the identification of the SAC. Later mammalian homologs were found with conserved 
function. The SAC regulates entry into anaphase during mitosis. SAC activation occurs in the 
presence of unattached kinetochores or syntelic kinetochore attachment, attachment of sister 
chromatids to microtubules emanating from the same spindle pole. Activation of the SAC is 
regulated by the activity of the T-cell tyrosine kinase (TTK, also known as Mps1 or CT96) 
(X Liu and Winey, 2012).  
TTK 
  TTK is an evolutionarily-conserved protein kinase with homologs in yeast, xenopus, 
mice, rat, zebra fish, and drosophila (X Liu and Winey, 2012). The C-terminal kinase domain 
is highly conserved and kinase domain similarity is the main metric to identify homologs, yet 
the N-termini appear unrelated among species. In humans, TTK is an 857-amino acid (aa) 
97-kDa protein. The C-terminus contains the conserved kinase domain (aa 515-794) followed 
by an unstructured tail (aa 794-857). Previous work revealed that the tail is required for 
exogenous substrate recruitment (Sun et al., 2010). In addition, the extreme C-terminus 
contains a predicted nuclear localization signal (NLS)  (aa 852-857) (X Zhang et al., 2011). 
  Until recently the role of the much larger N-terminus of TTK has been poorly 
characterized. Expression of TTK N-terminus truncation mutants suggests that the N-
terminus was important for subcellular localization and protein stability, but the functional 
domains were unknown. Newly published studies confirm the role of the N-terminus and 
identify tetratricopeptide repeat motifs (TPR, aa 61-192) preceded by an N-terminal 
extension (NTE, aa 1-60). These protein binding motifs are important for TTK kinetochore 
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localization (Thebault et al., 2012; S Lee et al., 2012; Nijenhuis et al., 2013).  Additionally, 
two LXXLL motifs (aa 65-69, 80-84), commonly referred to as nuclear receptor boxes, were 
found to be important for nuclear translocation at the G2/M boundary (X Zhang et al., 2011). 
  TTK is also regulated by post-translational modifications. Ubiquitination is a process 
of covalently linking ubiquitin to a protein substrate. Whereas mono-ubiquitination is 
important for subcellular localization, poly-ubiquitination is generally a signal for protein 
degradation by the proteasome. TTK contains a single RXXL destruction box motif (D-Box, 
aa 256-259) that is recognized by the anaphase promoting complex, or cyclosome (APC/C) 
leading to ubiquitination of TTK and signaling for its degradation (Cui et al., 2010).  
  Phosphorylation also regulates TTK function and activity. TTK is auto-
phosphorylated as well as phosphorylated by other protein kinases. Mass spectrometry 
experiments have identified over 50 phosphorylation sites on TTK (J Kang et al., 2007; Daub 
et al., 2008; Guo et al., 2008; Jelluma, Brenkman, McLeod, et al., 2008; Oppermann et al., 
2009; Xu et al., 2009; Tyler et al., 2009; YH Yeh et al., 2009; Mayya et al., 2009; Kasbek et 
al., 2010; Iliuk et al., 2010; Olsen et al., 2010; Rigbolt et al., 2011; X Zhang et al., 2011; 
Grosstessner-Hain et al., 2011; Phanstiel et al., 2011; Kettenbach et al., 2011; Hegemann et 
al., 2011; Stokes et al., 2012; Franz-Wachtel et al., 2012; L Zhang et al., 2013; Zhou et al., 
2013; C-W Yeh et al., 2014). Although most of these studies only identified the sites of 
phosphorylation, several of these sites have been functionally characterized. Phosphorylation 
of TTK regulates subcellular localization (T12, S15, T288, and S821), protein stability 
(S281, T288, and Y811) (YH Yeh et al., 2009; Tyler et al., 2009; J Liu et al., 2013), and 
activation (T675, T676, and T686) (Mattison et al., 2007; W Wang et al., 2009). 
Characterizing the functional consequences of phosphorylation events on TTK and the 
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kinases responsible for these phosphorylation events will be required to understand the 
molecular role of TTK (Figure 5). 
  Originally identified in a screen using anti-phosphotyrosine antibodies, TTK mRNA 
and protein were observed in proliferating cells but not in resting cells. This study suggested 
that TTK may have a role in cell cycle regulation (Hogg et al., 1994). Soon after, it was 
discovered that TTK had a conserved role regulating progression from metaphase to 
anaphase in the cell cycle. Since that time TTK has been shown to regulate DNA damage 
response through phosphorylation of CHK2 and BLM (Wei et al., 2005; Leng et al., 2006), 
chromosomal alignment by phosphorylating Borealin (Jelluma, Brenkman, McLeod, et al., 
2008), and post-mitotic arrest through phosphorylating p53(Huang et al., 2009). TTK has 
also been shown to phosphorylate Smad2 and Smad3 but the downstream effects remain to 
be characterized (Zhu et al., 2007). TTK has also been shown to localize to centrosomes 
(Bayliss et al., 2012) and may play a similar role in centrosome duplication as observed in 
vertebrates (Fisk et al., 2004) (Figure 6). Although the mechanism is not completely 
understood, TTK responds to a yet-unidentified signal produced by unattached kinetochores 
to prevent anaphase onset by activating the SAC. The way the SAC prevents early anaphase 
onset is by inhibiting APC/C.  
APC/C 
  APC/C is a multi-subunit E3 ubiquitin ligase that ubiquitinates proteins containing a 
lysine-glutamate-asparagine (KEN) or D-BOX motifs. These proteins become 
polyubiquitinated and thereby targeted for proteosomal degradation by the 26S proteasome. 
APC/C requires association with cell division cycle 20 (Cdc20) or cell division cycle 20 
related 1 (Cdh1) to be active (Hagting et al., 2002). It is thought that Cdc20 and Cdh1 recruit
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Figure	  5.	  Domain	  structure	  of	  TTK.	  TTK	  protein	  contains	  a	  C-­‐terminal	  kinase	  domain	  (blue),	  tandem	  tetratricopeptide	  repeats	  (TPR,	  red)	  preceded	  by	  an	  N-­‐terminal	  extension	  (NTE,	  orange),	  and	  a	  single	  D-­‐Box	  (yellow).	  TTK	  also	  contains	  a	  nuclear	  localization	  peptide	  sequence	  at	  the	  extreme	  C-­‐terminus	  (blue	  lines)	  and	  tandem	  LXXLL	  motifs	  in	  the	  N-­‐terminus	  (green	  lines)	  required	  for	  nuclear	  accumulation.	  Validated	  phosphorylation	  sites	  with	  known	  functions	  are	  also	  displayed	  (black	  lines).	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Figure 6. TTK signaling. TTK  is activated downstream of unattached kinetochores by a 
yet-undefined mechanism. Trans- and auto-phosphorylation of T675, T676, T686 activate 
TTK and lead to downstream signaling. TTK phosphorylates multiple downstream substrates 
to mediate distinct cellular functions, yet gaps in the knowledge of the molecular signaling 
cascades remain unknown.
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ubiquitination substrates to APC/C by binding to both partners.  Cdc20 is important for 
regulating mitotic proteins in early mitosis, whereas APC/C binding to Cdh1 is important for 
the late stages of mitosis important for mitotic exit (Nasmyth, 2005; Lehman et al., 2010).  
  APC/CCdc20 has several well-characterized ubiquitination substrates among which are 
securin, and cyclin B. Securin is a chaperone protein responsible for inhibiting the protease 
activity of separase. Separase is a protease that cleaves cohesin, a multi-subunit protein that 
holds sister chromatids together, thus destroying the link between the sister chromatids in 
preparation for segregation during anaphase. Cyclin B is an activator of the cyclin-dependent 
kinase 1 (Cdk1), whose activities is responsible for progression through the cell cycle. Cyclin 
B/Cdk1 inhibits separase through direct phosphorylation. The simultaneous degradation of 
both securin and cyclin B by the APC/C relieve the inhibition of separase, allowing for 
separation of sister chromatids during anaphase (Nasmyth, 2005).  
  It is of vital importance that APC/C remain inactive until proper alignment and 
attachment of microtubules to each sister chromatid to ensure mitotic fidelity. The SAC 
accomplishes this function by sequestering the APC/C co-activator CDC20. Previous reports 
have shown that active mitotic arrest-deficient 2-like-1 (Mad2) can bind directly to CDC20, 
thereby preventing its association with APC/C. Unbound Mad2 exists in two conformations, 
an inactive “open” form (O-Mad2) and an active “closed” form (C-Mad2). As a monomer 
Mad2 is mostly found in the open, inactive state. C-Mad2 is found stably bound to a mitotic 
arrest-deficient 1-like-1 (Mad1) homodimer. Activation of O-Mad2 is thought to occur 
through a template model whereby O-Mad2 forms a homodimer with C-Mad2 that is bound 
to Mad1. Dimerization changes the conformation of O-Mad2 to C-Mad2. At this point the 
recently activated C-Mad2 can release the C-Mad2/Mad1 complex and bind to CDC20, 
	   22	  
weakly capturing it. The binding of C-Mad2 and CDC20 is strengthened by the subsequent 
binding of budding uninhibited by benzimidazoles 1 mitotic checkpoint serine/threonine 
kinase B (BubR1) and budding uninhibited by benzimidazoles 3 (Bub3) to form the mitotic 
checkpoint complex (MCC). In the MCC, CDC20 is directly bound to C-Mad2 and BubR1, 
thus strengthening the sequestering effect. However, in the cytosol O-Mad2 cannot interact 
with the C-Mad2/Mad1 complex because the dimerization site is masked by p31comet, which 
is a Mad2 binding protein that functions as a negative regulator of the SAC. p31comet  
outcompetes O-Mad2 for the C-Mad2 dimerization site due to its higher affinity. To 
overcome this negative regulation, the Mad1/C-Mad2/p31comet complex is recruited to 
unattached kinetochores. Although the mechanism is still under investigation, at unattached 
kinetochores p31comet disassociates from the C-Mad2/Mad1 dimer, allowing O-Mad2 to bind, 
convert to the closed conformation, and subsequently bind CDC20 (Figure 7).  
  TTK is required to recruit Mad2 to unattached kinetochores (Abrieu et al., 2001; 
Martin-Lluesma et al., 2002; Santaguida et al., 2010; Maciejowski et al., 2010; Sliedrecht et 
al., 2010; Hewitt et al., 2010). Although TTK does not phosphorylate Mad2, TTK has been 
shown to phosphorylate Mad1 in vitro (Hardwick et al., 1996). Furthermore, catalytic 
inhibition of TTK prevents hyper-phosphorylation of Mad1, maintenance of C-Mad2/Mad1 
complex to the kinetochore, and continual recruitment of O-Mad2 to kinetochores (Hewitt et 
al., 2010; Tipton et al., 2013). These and other findings demonstrate the essential role of 
TTK for sustained SAC function. Inhibition of TTK with either siRNA depletion or 
pharmacologic inhibition of TTK catalytic activity causes SAC silencing, resulting in an 
accelerated mitotic transit time and aberrant chromosomal separation. Ultimately the result of 
TTK inhibition is massive cellular aneuploidy that is incompatible with cell viability 
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(Schmidt et al., 2005; Tighe et al., 2008; Jelluma, Brenkman, van den Broek, et al., 2008; 
Kwiatkowski et al., 2010).  
  The deregulation of the cell cycle by disrupting mitotic checkpoint machinery is an 
attractive approach for cancer therapy (Janssen and Medema, 2011; Aarts et al., 2013). The 
requirement of TTK in proper SAC activation makes it an attractive target to inappropriately 
force cancer cells through the cell cycle.  To explore this hypothesis, numerous 
pharmacologic inhibitors have been developed to selectively inhibit TTK, including AZ3146 
(Hewitt et al., 2010), Reversine (Santaguida et al., 2010), MPS1-IN-1, MPS1-IN-2 
(Kwiatkowski et al., 2010), MPS-IN-3 (Tannous et al., 2013), MPS-BAY1, MPS-Bay2a 
(Jemaà et al., 2013), NMS-P715 (Colombo et al., 2010), and MPI-0479605 (Tardif et al., 
2011). Pharmacologic inhibition of TTK has been shown to decrease cell proliferation of 
breast cancer cell lines in vitro and in vivo (Daniel et al., 2011; Maire et al., 2013).  In 
addition, inhibition of TTK has been shown to decrease growth of other cancer cell lines 
including colorectal (Kwiatkowski et al., 2010; Tardif et al., 2011; Jemaà et al., 2013), lung 
(Tardif et al., 2011), glioblastoma (Tannous et al., 2013), cervical (Tardif et al., 2011; Jemaà 
et al., 2013), pancreas  (Slee et al., 2013), and malignant melanoma (Colombo et al., 2010).  
  These studies demonstrate the importance of TTK for continued growth of PDAC and 
to suppress chromosomal instability. Genomic instability, of which chromosomal instability 
is a component, is thought to drive cancer. Identification and characterization of the driving 
mutations and expression profiles in PDAC may identify vulnerabilities in PDAC to explore 
as therapies. 
Genetics of pancreatic ductal adenocarcinoma 
  Progression from non-invasive precursor lesions towards PDAC is believed to occur 
through step-wise accumulation of genetic mutations (Figure 8) 
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Figure	  7.	  The	  spindle	  assembly	  checkpoint.	  TTK	  promotes	  kinetochore	  localization	  of	  a	  Mad1	  homodimer	  bound	  to	  closed	  Mad2.	  Kinetochore	  binding	  causes	  the	  release	  of	  p31comet.	  O-­‐Mad2	  (green	  circles	  labeled	  O)	  binds	  to	  closed	  Mad2	  (red	  circles	  labeled	  C)	  and	  becomes	  activated	  and	  converts	  to	  closed	  Mad2	  that	  can	  now	  bind	  and	  sequester	  CDC20.	  Further	  binding	  of	  BubR1	  and	  Bub1	  stabilizes	  the	  complex	  and	  continues	  sequesteration	  of	  CDC20	  to	  prevent	  APC/C	  activation.	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Figure 8. The morphological and genetic progression of PDAC. Normal	   duct	   epithelium	  progresses	   to	   invading	   carcinoma	   through	   a	   series	   of	   histologically	   defined	   precursor	  lesions.	   Accumulation	   of	   genetic	   mutations	   drive	   development	   from	   early	   stage	   PanIN1	  lesions	   to	   advanced	   PanIN3	   lesions	   that	   demonstrate	   increased	   dysplasia	   including	  elongation	  of	  the	  cell	  morphology,	  nuclear	  atypia	  and	  dysplastic	  growth.	  Development	  into	  invasive	   PDAC	   includes	   degradation	   of	   the	   extracellular	   matrix	   (orange)	   and	   infiltration	  through	  the	  stroma	  (green).	  Activating	  point	  mutations	  in	  KRAS	  occur	  early	  in	  the	  process	  and	  are	   followed	  by	   inactivating	  mutations	   in	  p16ink4a,	   SMAD4,	  p53,	  and	  BRCA2	  relatively	  later	  in	  the	  process.	  Adapted	  from	  Hruban	  RH	  et	  al.,	  (2008)	  Int	  J	  Clin	  Exp	  Pathol	  1:306-­‐316.	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(Hruban et al., 2000; JJ Yeh and Der, 2007). One of the earliest mutations to arise in the 
development of PDAC, and most common, occurring in greater than 90% of tumors, is 
within the KRAS (Kirsten rat sarcoma) gene. KRAS is a member of the Ras family of small 
guanine triphosphatases (GTPases). Ras proteins act as a molecular switch to relay signals 
between the growth-promoting stimulation received at cell surface to the nucleus by initiating 
signal transduction cascades. In the nucleus, transcription factors convert the signals into 
gene expression changes that are more permissive of growth. Mutations in KRAS cause 
persistent signaling, even in absence of the growth-promoting signals, thereby driving PDAC 
development.   
  Work in mouse models of pancreatic cancer informs us that Ras mutations alone are 
sufficient to transform normal cells into carcinoma, however, it takes an extended period of 
time to form a tumor. The vast majority of pancreatic cancers required more than just Ras 
mutations. Whole genome sequencing of human primary PDAC tumors reveals that most 
tumors have an average of 48 genetic alterations. Some of these mutations cause activation of 
oncogenes, including KRAS and epidermal growth factor receptor (EGFR), as well as 
mutations that inactivate tumor suppressors, such as tumor protein 53 (TP53), breast cancer 
type-2 susceptibility protein (BRCA2), mothers against decapentaplegic homolog 4 (SMAD4, 
also known as DPC4) and cyclin dependent kinase 4 inhibitor A (p16ink4a) (S Jones et al., 
2008). Although these mutations are more common in PDAC, each tumor is made up of 
unique set of acquired mutations. 
  Some mutations may be biologically inert and have little influence on tumor biology 
and are often referred to as passengers. Although the passenger genes may not provide a 
selective growth advantage for oncogenesis, they are of potential value as diagnostic 
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markers. Unlike traditional biomarkers, mutated protein and DNA are produced only by 
tumor cells (Q Wang et al., 2011).  
  There are also mutations that directly provide cancer cells with a growth advantage; 
these mutations are referred to as driver mutations. Driver mutations often occur in key 
signal transduction nodes that regulate essential biological processes such as survival, 
proliferation, cellular invasion and motility, and apoptosis. Similarly to mutant KRAS, driver 
mutations often perturb cellular signaling resulting in altered transcription factor activity and 
gene expression changes. A genome-wide identification gene expression change, hereafter 
referred to as a gene signature, is one method to investigate the growth promoting 
consequences of driver mutations to tumor biology.  
Gene expression profiling 
  It is now widely appreciated that cancer is a heterogeneous disease. Therefore, we 
need to improve our understanding of the molecular classification of patients to personalize 
the treatment plan. During tumor progression mutations will drive changes in gene 
expression to promote growth, and tumors may develop dependencies on key overexpressed 
genes. Often the tumor may become addicted to the overexpressed gene product to an extent 
where if the gene is removed the tumor is no longer viable. There is a great need to identify 
the products of overexpressed genes to which tumors become addicted. One way to 
accomplish this is by analysis of gene expression profiles of patient tumors. Statistical 
methods can be employed to determine a minimal number of genes that can stratify patients 
into high- and low-risk groups based on patient survival. Previously, gene signatures have 
been identified in multiple cancers with the ability to stratify patients into high- and low-risk 
groups associated with overall survival (Sørlie et al., 2001; Beer et al., 2002; van de Vijver et 
al., 2002; Eschrich et al., 2005).  Not only does this method help identify biomarkers to help 
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dictate the treatment plan but it also generates a list of potential addictions of the tumor. In 
this way, genes that compose a gene signature can also be investigated for their potential use 
for therapeutic intervention.   
  Changes in gene expression occur through many molecular mechanisms including 
aneuploidy, gene amplification (Chou et al., 2013), aberrant cell signaling (Singh et al., 
2009), aberrant micro RNA (miRNA) expression (Szafranska et al., 2007), and epigenetic 
changes such as DNA methylation or histone modifications (McCleary-Wheeler et al., 2013; 
Nones et al., 2014) (Figure 9). Technological advances, such as complementary DNA 
(cDNA) microarrays and whole transcription RNA sequencing (RNA-seq), have provided a 
means to investigate gene expression on a genome-wide scale.  
  Several studies investigating aberrant gene expression are providing insight and 
understanding of the molecular biology that promotes malignant transformation, important to 
development of both diagnostic tools and therapeutic targets. Comparing the transcriptome of 
micro-dissected PanIN I-III precursor lesions with normal pancreas identified 1251 
differentially regulated genes. Interestingly, only 47 differentially expressed genes were 
identified in PanIN-1B samples whereas PanIN2 had 438 differentially expressed genes 
when compared to normal pancreas. Of these genes, 30-60% of aberrantly expressed PanIN 
genes were also aberrantly regulated in PDAC, suggesting a functional role in disease 
progression (Buchholz et al., 2005).  
  The utility of gene expression profiling as a diagnostic tool is an area of current 
investigation. Comparison of gene expression profiles of normal pancreas and chronic 
pancreatitis with PDAC cell lines and primary tumors identified differential expression of 
158 genes in PDAC (Logsdon et al., 2003). These genes not only provide new insights into 
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the molecular development of PDAC but could also be useful in differentiating between 
chronic pancreatitis and invasive PDAC, which has been a challenge for clinicians when the 
histology is inconclusive (Klöppel and Adsay, 2009). 
  In addition to diagnostic use, gene expression profiles may identify genes of 
biological significance for PDAC development. Comparison of the gene expression profiles 
of normal pancreas with pancreatic cancer cell lines and primary tumors have identified an 
enrichment of genes involved with specific molecular pathways in PDAC. One study 
identified 149 differentially up-regulated genes, 103 genes not previously identified in PDAC 
associated with cell-cell and cell-matrix interactions, cytoskeleton remodeling and calcium 
homeostasis (Iacobuzio-Donahue, Maitra, et al., 2003). Further investigation into these 
pathways known to be involved with invasive properties of the cell may 
provide insight into the mechanism of metastasis and potential identify therapeutic targets. 
   Recent whole-genome profiling of PDAC performed by the International Cancer 
Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA, unpublished data from 
https://tcga-data.nci.nih.gov/tcga/) have unveiled vast heterogeneity in PDAC (Biankin et al., 
2012). Clustering of the gene expression of primary PDAC tumors demonstrates that 
similarities between tumors exist, perhaps subtypes of PDAC (Lowe et al., 2007). Gene 
expression analysis in breast cancer led to the identification of disease subtypes associated 
with patient prognosis (Sørlie et al., 2001). Assuming that subtypes exist, identification of 
subtypes of disease may help identify vulnerabilities and dependencies of PDAC that can be 
used to guide therapeutic choices as well as identify novel therapeutic targets.  
Summary 
  Despite the low overall survival of PDAC patients, about 20% of patients with 
resectable PDAC will survive for five years following surgery. Although the reasons are not  
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Figure	  9.	  Mechanisms	  of	  aberrant	  gene	  expression.	  Aberrant	  gene	  expression	  occurs	  through	  many	  mechanisms	  in	  the	  cell.	  Mutation	  (red	  callout)	  can	  aberrantly	  phosphorylate	  (P)	  and	  activate	  MAPK	  signaling	  cascades	  resulting	  in	  enhanced	  transcription	  factor	  (TF)	  phosphorylation	  leading	  to	  nuclear	  translocation	  where	  it	  can	  enhanced	  transcription	  by	  RNA	  polymerase	  II	  (Pol	  II).	  Copy	  number	  alterations	  including	  gene	  duplication	  (red	  DNA)	  can	  also	  enhance	  gene	  expression.	  Aberrant	  epigenetic	  changes	  in	  DNA	  methylation	  (Me)	  or	  chromosomal	  structure	  can	  enhance/inhibit	  transcription	  factor	  accessibility	  to	  gene	  promoters	  and	  affect	  transcription.	  Enhanced	  expression	  of	  miRNA	  can	  increase	  RNA-­‐induced	  silencing	  complex	  (RISC)	  and	  regulate	  mRNA	  expression.	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completely known, it has been hypothesized that the long-term survivors may have a less 
aggressive form of the disease. Elucidating the molecular differences between more and less 
aggressive tumors could be helpful in determining a patient’s therapy. In addition, by gaining 
a more complete understanding of tumor biology, including its addictions, dependencies, 
disposition for invasion and metastatic spread, we can better understand how to treat each 
newly diagnosed pancreatic cancer patient.  
  Here we have discussed the development, progression, characteristics, and therapy of 
PDAC. PDAC is a heterogeneous disease but there are mutations that are more common such 
as the mutational activation of the oncogene KRAS, and inactivation of the tumor suppressors 
TP53, p16ink4a, and SMAD4. These driver mutations often result in changes in gene 
expression whose gene products may represent dependencies. By studying the changes in 
gene expression in in vitro and in vivo models of PDAC, we can identify novel diagnostic 
approaches, therapeutically useful targets, and further understand the molecular biology of 
PDAC to ultimately lead to advances in the way that we treat pancreatic cancer.  
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Chapter II. 
A six-gene signature predicts survival of patients with localized pancreatic ductal 
adenocarcinoma. 
Overview 
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease. For patients with 
localized PDAC, surgery is the best option, but with a median survival of less than 2 years 
and a difficult and prolonged postoperative course for most, there is an urgent need to better 
identify patients who have the most aggressive disease. 
We analyzed the gene expression profiles of primary tumors from patients with 
localized compared to metastatic disease and identified a six-gene signature associated with 
metastatic disease. We evaluated the prognostic potential of this signature in a training set of 
34 patients with localized and resected PDAC and selected a cut-point associated with 
outcome using X-tile. We then applied this cut-point to an independent test set of 67 patients 
with localized and resected PDAC and found that our signature was independently predictive 
of survival and superior to established clinical prognostic factors such as grade, tumor size, 
and nodal status, with a hazard ratio of 4.1 (95% confidence interval [CI] 1.7–10.0). Patients 
defined to be high-risk patients by the six-gene signature had a 1-year survival rate of 55% 
compared to 91% in the low-risk group. 
Our six-gene signature may be used to better stage PDAC patients and assist in the 
difficult treatment decisions of surgery and to select patients whose tumor biology may 
benefit most from neoadjuvant therapy. The use of this six-gene signature should be 
investigated in prospective patient cohorts, and if confirmed, in future PDAC clinical trials, 
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its potential as a biomarker should be investigated. Genes in this signature, or the pathways 
that they fall into, may represent new therapeutic targets. 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC), comprising over 90% of all pancreatic 
cancers, remains a lethal disease with an estimated 232,000 new cases, 227,000 deaths per 
year worldwide, and a less than 5% 5-year survival rate (Parkin et al., 2005; Boyle et al., 
2008). Currently the standard of care for the 20% of patients with localized disease is surgery 
followed by chemotherapy, and in some cases radiation. Unfortunately, despite the use of 
adjuvant therapy, median survival remains at best 23 months (Neuhaus et al., 2008). It is 
important to note, however, that up to 27% of patients with resected PDAC can survive for 5 
year (Conlon et al., 1996; NA Ahmad et al., 2001; Cleary et al., 2004; Han et al., 2006; 
Winter et al., 2006; Ferrone et al., 2008; Schnelldorfer et al., 2008). However, in studies 
examining actual long-term survivors (Conlon et al., 1996; NA Ahmad et al., 2001; Cleary et 
al., 2004; Han et al., 2006; Winter et al., 2006; Ferrone et al., 2008; Schnelldorfer et al., 
2008), only two have found that adjuvant therapy was associated with improved survival 
(NA Ahmad et al., 2001; Winter et al., 2006). In addition, randomized controlled trials of 
gemcitabine-based chemotherapy demonstrate an improvement in median survival of at best 
3 months (Neuhaus et al., 2008; Ueno et al., 2009). One possible conclusion from these 
studies is that tumor biology dictates outcome and that our current adjuvant therapy has only 
a modest impact on altering a patient’s course. 
Hypothesizing that the dismal outcome of patients with localized disease is due to the 
presence of micrometastatic disease, current clinical investigation has focused on 
preoperative or neoadjuvant therapy (Evans et al., 2008; Varadhachary et al., 2008). This 
approach, in which patients who cannot tolerate the stress of therapy or who develop 
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metastatic disease during treatment are spared surgery, has demonstrated an overall survival 
of 34 months in this highly selected patient population (Evans et al., 2008; Varadhachary et 
al., 2008). Therefore the ability to select patients who would most benefit from a neoadjuvant 
approach may be important. One way to select these individuals is to define a prognostic 
gene signature that can identify patients with more aggressive tumor biology upfront. 
Expression profiling of PDAC has lead to further studies of additional molecular 
diagnostic and prognostic markers (Grützmann, Saeger, et al., 2004; Grützmann et al., 2005; 
Goggins, 2007; Grote and Logsdon, 2007; Tonini et al., 2007; Kolbert et al., 2008). 
However, the search for genes of biological significance in these large datasets continues to 
be challenging. One approach to identify genes or pathways that are biologically relevant is 
to study those that are of prognostic significance (JJ Yeh, 2009). Lowe and colleagues found 
differential gene expression changes associated with nodal status in primary PDAC (Kim et 
al., 2007), suggesting that molecular differences in primary PDAC do exist. We hypothesized 
that by comparing primary PDAC tumors at the extremes of disease, we would identify 
molecular changes reflective of differences in biology within primary PDAC tumors. 
Experimental Procedures 
Patients 
PDAC samples from 15 patients with resected primary PDAC from the University of 
North Carolina at Chapel Hill (UNC) and 15 patients with metastatic PDAC from the 
University of Nebraska Medical Center Rapid Autopsy Pancreatic Program (NEB) were used 
to derive differentially expressed genes associated with metastatic disease. For the NEB 
samples, human pancreatic tumors from decedents who had previously been diagnosed with 
PDAC, and who generously consented to post mortem examinations, were obtained from the 
institutional review board (IRB)- approved NEB Tissue Bank. To ensure minimal 
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degradation of tissue, organs were harvested within 3 h post mortem and the specimens flash 
frozen in liquid nitrogen. 
The training cohort included 34 patients with resected PDAC from Johns Hopkins 
Medical Institutions (JHMI). The testing or validation cohort included patients from two 
institutions: 48 from Northwestern Memorial Hospital (NW) and 19 from North Shore 
University Health System (NSU). All samples were collected between 1999 and 2007 at the 
time of operation and flash frozen in liquid nitrogen after approval by each individual IRB. 
The UNC IRB approved use of all de-identified samples for this study. All available samples 
were reviewed by a single pathologist (KAV). De-identified data including tumor, node, and 
metastasis (TNM), grade or differentiation, margin status, and survival were available for the 
majority of patients. 
RNA isolation and Microarray Hybridization 
All RNA isolation and hybridization was performed on Agilent (Agilent 
Technologies) human whole genome 4×44 K DNA microarrays and at UNC. RNA was 
extracted from macro-dissected snap-frozen tumor samples using Allprep Kits (Qiagen) and 
quantified using nanodrop spectrophotometry (Thermo Scientific). RNA quality was assessed 
with the use of the Bioanalyzer 2100 (Agilent Technologies). RNA was selected for 
hybridization using RNA integrity number and by inspection of the 18S and 28S ribosomal 
RNA. Similar RNA quality was selected across samples. One microgram of RNA was used 
as a template for DNA preparations and hybridized to Agilent 4×44 K whole human genome 
arrays (Agilent Technologies). cDNA was labeled with Cy5-dUTP and a reference control 
(Stratagene) was labeled with Cy3-dUTP using the Agilent (Agilent Technologies) low RNA 
input linear amplification kit and hybridized overnight at 65°C to Agilent 4×44 K whole 
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human genome arrays (Agilent Technologies). Arrays were washed and scanned using an 
Agilent scanner (Agilent Technologies). The data are publicly available in Gene Expression 
Omnibus database (http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?acc = GSE21501). 
Microarray and Statistical Analysis 
All array data were normalized using Lowess normalization. Data were excluded for 
genes with poor spot quality or genes that did not have mean intensity greater than 10 for one 
of the two channels (green and red) in at least 70% of the experiments. The log2 ratio of the 
mean red intensity over mean green intensity was calculated for each gene and went through 
LOWESS normalization (YH Yang et al., 2002). Missing data were imputed using the k-
nearest neighbors imputation (KNN) with k = 10 (Troyanskaya et al., 2001). A distance 
weighted discrimination (DWD) was used to detect the systematic biases between the 
different datasets and then global adjustments made to remove these biases (Benito et al., 
2003). Genes that were significantly up- or down-regulated were identified using significance 
analysis of microarrays (SAM) (Tusher et al., 2001). Two centroids were created using the 
mean gene expression profile of this significant gene list from the derivation set and used to 
develop a single sample predictor (SSP, nearest centroid algorithm) (Hu et al., 2006) for an 
objective classifier. After DWD, the SSP was applied to a 34-patient training set where any 
new sample was compared to the resected centroid and assigned by the SSP distance function 
to the resected centroid using (1 2 Pearson correlation coefficient). The X-Tile software 
program, which assigns a two-population log-rank value to each sample and then determines 
the best cut-point, was used to determine the best threshold for classifying samples into high- 
and low-risk categories (Camp et al., 2004). X-Tile predicted that the (12 Pearson correlation 
coefficient) distance of 1 would be the appropriate cut-point to stratify patients into a high- 
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and low-risk group (p = 0.006). A second independent validation cohort was then used as a 
test set using this predetermined cut-point to evaluate outcome. 
Survival analysis was performed using the statistical software programs R, the R-
package ‘‘survival,’’ and SPSS (SPSS, Inc.). Overall survival (OS) was analyzed using the 
Kaplan-Meier product-limit method and the significance of our variables was measured by 
the log-rank test. The Fisher exact test was used to analyze associations between two 
variables, the Pearson Chi-square test was used to analyze association between more than 
two variables. Multivariable analysis and analysis of continuous and ordinal variables was 
performed using the Cox proportional hazards regression method. 
Tissue Microarrays 
Tissue microarrays (TMAs; UNC2) were prepared from formalin-fixed paraffin-
embedded tissue sections using a 2-mm punch. The arrays contained triplicate cores of 
matched normal and tumor tissue as well as chronic pancreatitis when available, from each 
patient. We prepared 5-µm sections from each TMA block. Hematoxylin and eosin stained 
slides from each TMA block were reviewed by a pathologist (KAV) to ensure that tissues 
were scored accurately. 
Immunohistochemistry 
Slides with 5-µM sections from the paraffin-embedded specimens were 
deparaffinized and rehydrated. The slides were then subjected to alkaline heat antigen-
retrieval using 1% Tris EDTA for 20 min in a steamer. All slides were incubated with 3% 
H2O2 for 5 min and washed with TBS. The slides were further treated with protein block 
solution (bovine serum albumin) for 20 min. The sections were incubated with primary KLF6 
1:150 antibody (sc-7158, Santa Cruz Biotechnology) for 60min at room temperature.  
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Figure 10. Identification, development, and application of a six-gene signature for 
PDAC. Clustering of (A) the six genes defined by SAM evaluation of the metastatic 
compared to nonmetastatic primary PDAC using a false discovery rate of 5%; (B) patient 
samples into high- and low-risk groups in a training set of 34 patients with localized and 
resected PDAC using the X-tile determined cut-point of a Pearson correlation coefficient of 
zero; (C) patient samples into high- and low-risk groups in an independent test set of 67 
patients with localized and resected PDAC using the predetermined cut-point of zero. 
Kaplan-Meier overall survival of (D) the training set classified into high- and low-risk groups 
according to the X-tile determined cut-point of a Pearson correlation coefficient of zero; (E) 
and the independent test set classified into high- and low-risk groups according to the same 
predetermined cut-point. From: Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
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Following a TBS wash, the slides were incubated with secondary labeled Polymer-HRP anti- 
rabbit (Dako K4002) for 30 min. This was followed by a 5-min incubation with the substrate- 
chromogen, 3,39-diaminobenzidine (Vector SK-4100). The sections were counterstained 
with Harris hematoxylin. Positive KLF6 staining was defined as when more than 5% of cells 
expressed the marker and graded from 0 (no staining) to 4 (strong staining). The results of 
each protein marker were then expressed as intensity (I) and proportion (P) of positive 
epithelial cells and the score as the product of I and P (Hoos and Cordon-Cardo, 2001; JJ Yeh 
et al., 2009). All stained slides were reviewed in a blinded fashion (JMA). 
Results 
Patient and Tumor Characteristics 
In order to study the extremes of PDAC tumor biology, we collected a diverse set of 
resected PDAC specimens from patients with and without metastases. As the tumor 
microenvironment is increasingly recognized to play a critical role in tumorigenesis (Allinen 
et al., 2004; Mueller and Fusenig, 2004; Comoglio and Trusolino, 2005; Troester et al., 
2009), tissues were macro-dissected in order to preserve the normal adjacent tissue and 
stroma of the tumors. The characteristics of the dataset used to derive the signature 
(derivation set) comprised 15 primary resected PDAC tumors (UNC1) and 15 primary 
tumors from patients with metastatic PDAC (NEB). The training set comprised 34 patients 
with primary PDAC and the independent validation test set comprised 67 patients with 
primary PDAC (Tables 4 and 5). There were no differences in RNA quality between the 
decedent and resected PDAC samples. Available treatment data of the patients in the training 
and test sets are also shown. One of 15 (7%) UNC1 patients received preoperative or 
neoadjuvant chemotherapy and 11/15 (73%) NEB patients received chemotherapy less than 6 
months prior to death. No patient in the 34-patient training set received neoadjuvant
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Table 4. Patient, tumor, and treatment characteristics in the 
derivation set. 
Demographics (Derivation Set) NEB, n=15 UNC, n=15 
Median follow-up (months) NA 6 (1-35) 
T stage 
   1 NA - 
   2 NA 2 (13%) 
   3  NA 12 (80%) 
   4 NA 1 (7%) 
N stage 
   0 NA 7 (47%) 
   1 NA 8 (53%) 
M stage 
   0 0 15 (100%) 
   1 15 0 
Grade 
   1 NA 2 (14%) 
   2 NA 8 (57%) 
   3 NA 4 (29%) 
Margin 
   Negative NA 12 (80%) 
   Positive NA 3 (20%) 
Neoadjuvant therapy 
   No NA 14 (93%) 
   Yes NA 1 (7%) 
Adjuvant Therapy 
   No NA 11 (73%) 
   Yes NA 4 (27%) 
Chemotherapy 
   No 3 (20%) NA 
   Yes 12 (80%) NA 
Median Survival (months) NA 9 (1-35) 
NA, not available 
 
From Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
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Table 5. Patient, tumor, and treatment characteristics in the training and testing sets. 
Demographics  JHMI 
(Training Set), 
n=34 
NW/NSU 
(Testing Set), 
n=67 
UNC2 (TMA), 
n=50 
Median follow-up (months) 14 (2-54) 17 (2-59) 11 (0-51) 
T stage  
   1 - 2 (3%) 5 (10%) 
   2 6 (18%) 10 (16%) 8 (16%) 
   3 27 (79%) 51 (81%) 32 (66%) 
   4 1 (3%) - 4 (8%) 
N stage  
   0 2 (6%) 25 (38%) 15 (31%) 
   1 32 (94%) 41 (62%) 34 (69%) 
M stage  
   0 34 (100%) 67 (100%) 47 (94%) 
   1 0 0 2 (4%) 
Grade  
   1 1 (3%) 2 (3%) 2 (4%) 
   2 13 (38%) 34 (54%) 26 (52%) 
   3 20 (59%) 27 (43%) 20 (40%) 
Margin  
   Negative NA 51 (80%) 7 (14%) 
   Positive NA 13 (20%) 2 (4%) 
Neoadjuvant therapy  
   No 34 (100%) 65 (97%) 7 (14%) 
   Yes 0 2 (3%) 1 (2%) 
Adjuvant Therapy  
   No NA 30 (45%) NA 
   Yes NA 37 (55%) NA 
Median Survival (months) 13 (2-54) 21 (3-59) 12 (0-51) 
NA, not available 
 
From: Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
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chemotherapy. Only 3% (2/67) of patients in the test set received neoadjuvant chemotherapy 
and 45% (30/67) of patients received postoperative or adjuvant chemotherapy. 
Gene Expression Differences in Nonmetastatic and Metastatic Primary Tumors 
We hypothesized that we could enrich for molecular differences in primary PDAC, 
which may be clinically and biologically relevant, through examining primary tumors 
representing opposite spectrums of PDAC: early (localized) and late (metastatic) stage. To 
accomplish this, we compared nonmetastatic (UNC1) with metastatic (NEB) primary PDAC 
tumors. As the methods of procurement for these tumors differed, we used DWD to identify 
systematic biases between the two datasets (Benito et al., 2003). This method has been used 
previously to successfully combine three breast cancer datasets across three microarray 
platforms (Hu et al., 2006), across species (Herschkowitz et al., 2007), and across multiple 
datasets (Oh et al., 2006; Lu et al., 2006). We therefore used DWD to adjust for the 
systematic biases between the UNC1 and NEB datasets by taking advantage of the fact that 
each dataset also had 15 normal pancreas samples assayed. In short, we used DWD to adjust 
these 15 tumor-normal pairs from both datasets to have similar distributions in principal 
component (PC) 16PC 2 space. After the DWD adjustment, we used SAM to identify 
differentially expressed genes (Tusher et al., 2001; YH Yang et al., 2002). Using a false 
discovery rate of 5%, we identified six genes that were differentially overexpressed between 
nonmetastatic and metastatic primary tumors: FBJ murine osteosarcoma viral oncogene 
homolog B (FOSB), Kruppel-like factor 6 (KLF6), nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, zeta (NFKBIZ, IKBZ, MAIL), ATPase H+/K+ exchanging, 
alpha polypeptide (ATP4A), germ cell associated 1 (GSG1), and sialic acid binding Ig-like 
lectin 11 (SIGLEC11) (Figure 10A; Table S1, available online at 
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http://www.plosmedicine.org/). 
Development of a Classifier Using the Six-Gene Signature 
We examined the relationship of our six-gene signature to outcome using a training 
set of 34 patients with localized and resected PDAC. After identifying and adjusting for 
systematic bias using DWD (Benito et al., 2003), a resected centroid-based predictor (Hu et 
al., 2006) was created using the 30 samples in the derivation dataset. The centroid was then 
applied to the DWD-adjusted training set of primary PDAC patients to determine the 
performance of the six- gene signature. X-tile (Camp et al., 2004) was used to determine the 
optimal distance function to the centroid cut-point for classifying this training set of patients 
into high-risk and low-risk groups on the basis of survival (Figure 10B and 10D). The 
optimal cut-point occurred at a Pearson correlation coefficient of zero (p = 0.006) with 
patients with Pearson correlation coefficients greater than zero in the low-risk and less than 
zero in the high-risk groups. 
Application of the Six-Gene Signature to an independent Validation Cohort of 67 
Patients 
In order to evaluate the performance of the cut-point determined by X-tile (Camp et 
al., 2004), we applied the cut-point to an independent validation test set of 67 patients with 
primary PDAC. Our predetermined Pearson correlation coefficient cut-point of zero distance 
to the centroid successfully stratified patients into high- (n=42) and low-risk groups (n=25) 
with a median overall survival (OS) of 15 versus 49 months (p = 0.001) (Figure 10C and 
10E). Patients in the high-risk group had 1-, 2-, and 3-y estimated survival rates of 55%, 
34%, and 21%, compared to 91%, 64%, and 56% in the low-risk group. 
Previous studies in PDAC have found that nodal status is the most predictive of 
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outcome for patients with localized PDAC (Sohn et al., 2000). We compared our prognostic 
signature to current clinical prognostic benchmarks. We found that tumors that were node 
positive (p=0.091) and grade 2 or 3 trended towards a shorter survival (p = 0.080). Neither T 
stage (p = 0.977) nor margin status (p = 0.223) were prognostic in this cohort. Treatment 
with adjuvant chemotherapy (p=0.699) or with neoadjuvant chemotherapy (p=0.409) was 
also not prognostic, although only two patients received neoadjuvant chemotherapy. We 
found no gene expression changes between the tumors of the two patients who received 
neoadjuvant chemotherapy and the tumors of patients who received no treatment prior to 
surgery. 
An important feature of any prognostic signature is that it should be independent or 
additive to currently used clinicopathologic prognostic criteria. We therefore compared the 
prognostic importance of our molecular signature in the setting of grade (p = 0.417), nodal 
status (p = 0.381), T stage (p = 0.675), and margin status (p=0.295). We found that our six-
gene signature was the only independent predictor of survival in the 57 patients with 
complete data, with a hazard ratio of 4.1 (95% confidence interval 1.7–10.0) (Table 6). 
We also looked at whether our six-gene signature was confounded by available 
clinicopathological variables. We found no association between our molecular signature, and 
tumor size, grade, margin status, nodal status, and neoadjuvant or adjuvant chemotherapy in 
our independent test set (Table 7). 
KLF6 Expression in Primary PDAC 
In order to further validate the six-gene signature, we performed 
immunohistochemical analyses for KLF6, which showed a wide range of expression values 
between nonmetastatic versus metastatic samples (Figure 10A). To evaluate KLF6 protein
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Table 6. Cox proportional hazards regression analysis of the six-gene signature. 
Variable Hazard Ratio CI p-Value 
Six-gene signature 4.1 1.7-10.0 0.002 
   T stage - - 0.675 
   N stage - - 0.381 
   Grad - - 0.417 
Margin status - - 0.295 
CI, confidence interval. 
 
From: Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
 
 
Table 7. Relationship between the six-gene signature and clinicopathological variables. 
Variable Six-Gene Signature 
 High Risk Low Risk p-Value 
T stage  
   1 1 (50%) 1 (50%) 0.886 
   2 6 (60%) 4 (40%) - 
   3 33 (65%) 18 (35%) - 
N stage  
   0 13 (52%) 12 (48%) 0.203 
   1 28 (68%) 13 (32%) - 
Grade  
   1 1 (50%) 1 (50%) 0.788 
   2 22 (65%) 12 (35%) - 
   3 19 (70%) 8 (30%) - 
Margin  
   Negative 31 (59%) 22 (41%) 0.344 
   Positive 9 (75%) 3 (25%) - 
Neoadjuvant therapy  
   No 42 (65%) 23 (35%) 0.136 
   Yes 0 (0%) 2 (100%) - 
Adjuvant Therapy  
   No 24 (65%) 13 (35%) 0.801 
   Yes 18 (60%) 12 (40%) - 
 
From: Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
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Table 8. Comparison of individual genes in high- and low-risk groups Johns Hopkins 
Medical Institutions. 
 Group 1 (High Risk) Group 2 (Low Risk)  
 Average Stdev Average Stdev 
2 Sided 
Type 2 T-
Test 
SIGLEC11 0.0604 0.8489 -0.3163 0.7000 0.2098 
KLF6 0.3502 0.8063 0.1471 0.6985 0.2571 
FOSB -0.5505 .9013 0.4487 0.9527 0.0033 
ATP4A -0.1818 0.9529 -0.1826 0.7753 0.0010 
NFKBIZ 0.5668 0.7767 -0.1826 0.7753 0.0010 
GSG1 -0.2451 0.8350 0.1019 1.3196 0.1912 
Stdev, standard deviation 
From: Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
 
 
Table 9. Comparison of individual genes in high- and low-risk groups Northwestern 
Memorial Hospital/NorthShore University Health System 
 Group 1 (High Risk) Group 2 (Low Risk)  
 Average Stdev Average Stdev 
2 Sided 
Type 2 T-
Test 
SIGLEC11 0.1145 0.5742 -0.2116 0.7660 0.0492 
KLF6 0.5304 0.6399 -0.2474 0.5880 0.0000 
FOSB -0.9593 0.8241 0.9310 0.7750 0.0000 
ATP4A 0.0885 0.7960 0.1234 0.8217 0.8619 
NFKBIZ 0.1985 0.9682 -0.7227 0.8165 0.0001 
GSG1 0.0270 0.9123 0.1259 0.8499 0.6548 
Stdev, standard deviation 
From: Stratford JK et al. (2010) PLoS Med 7(7): e1000307.  
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Figure 11. Significance of KLF6 and Fos B expression in primary PDAC. (A) KLF6 
staining is significantly higher in PDAC compared to normal adjacent pancreas in an 
independent dataset of a 50-patient TMA (UNC2) as well as NEB samples used for the 
original analysis. (B) Kaplan-Meier overall survival of 50 patients classified by high and low 
KLF6 scores, using the median cutoff score of 1.5. (C) KLF6 immunostaining in the primary 
tumor of a patient who died of metastatic disease (ii) and in a resected primary tumor (iv). 
Minimal staining is seen in the matched normal adjacent tissue of both patients (i, iii). KLF6 
immunostaining in islet cells (i, white arrowhead). Arrows illustrate normal ductal 
epithelium. Black arrowheads illustrate tumor. From: Stratford JK et al. (2010) PLoS Med 
7(7): e1000307.  
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expression, we obtained another independent dataset of 50 patients represented on a TMA 
with matched normal, chronic pancreatitis, and PDAC (UNC2, Table 5). First, using the 
median score of 1.5 as the cutoff, we found that KLF6 expression was much higher in tumors 
compared to normal pancreas (p<0.001) (Figure 11A and 11C). KLF6 expression was strong 
in normal islet cells in agreement with a previous study (Figure 11Ci, white arrowhead) 
(Hartel et al., 2008). Second, we found that KLF6 expression with a score greater than 1.5 
(high) was associated with a shorter median survival of 11 months compared to 24 months 
for patients with KLF6 expression scores less than 1.5 (low) (p = 0.04) (Figure 11B). 
Discussion 
We profiled and compared nonmetastatic and metastatic primary PDAC tumors and 
identified a six-gene signature. Although this signature was not derived on the basis of 
outcomes, we show that it was prognostic in a true test set of resectable PDAC patients. 
Importantly, our six-gene signature was independently predictive of survival, stratifying 
patients with median survivals of 15 compared to 49 months, outperforming current 
pathological staging criteria, suggesting that our signature will be a powerful prognostic tool 
for patients with localized PDAC. 
PDAC continues to be a devastating disease with few long-term survivors. Surgery 
remains the standard therapy for patients diagnosed with resectable PDAC (Yeo et al., 1997). 
Yet with a median survival only of less than 2 y after surgery, the attendant postoperative 
mortality rate of 2%–6% (Yermilov et al., 2008; Eppsteiner et al., 2009), and postoperative 
complication and hospital readmission rates of 59% (DeOliveira, Winter, Schafer, 
Cunningham, Cameron, Yeo, and Clavien, 2006b; Yermilov et al., 2008), the decision for 
surgery should be made cautiously. Therefore, improved patient selection for therapy is 
necessary. For the majority of patients who cannot undergo surgery, gemcitabine 
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chemotherapy remains the best option, yet only 5%–10% of patients respond to the treatment 
(Abou-Alfa et al., 2006; Van Cutsem et al., 2009). Given the current therapeutic limitations, 
additional prognostic tools are needed to help a patient decide whether to have surgery, 
and/or neoadjuvant chemotherapy, or when to consider participation in a clinical trial. 
Our analysis identified a surprisingly small number of genes with differential 
expression between early compared to late stage primary PDAC (Table S1, available online 
at http://www.plosmedicine.org/). This finding suggests that primary PDAC may be largely 
homogenous from a global gene expression standpoint. Nonetheless, the differences that we 
identified appear to be clinically and therefore biologically important. Our findings of 
molecular differences in resected primary PDAC tumors suggest that there is subtle 
biological variation in these tumors that influences outcome. A review of previous published 
studies did not identify differential expression of our six genes (Crnogorac-Jurcevic et al., 
2001; 2002; Iacobuzio-Donahue et al., 2002; Logsdon et al., 2003; Iacobuzio-Donahue, 
Ashfaq, et al., 2003; Iacobuzio-Donahue, Maitra, et al., 2003; Crnogorac-Jurcevic et al., 
2003; Grützmann, Pilarsky, et al., 2004; Grützmann et al., 2005; Ishikawa et al., 2005; 
Segara et al., 2005; Kim et al., 2007; Lowe et al., 2007; Karanjawala et al., 2008). This 
finding is not surprising, as previous studies examined differential gene expression changes 
between either normal pancreas or chronic pancreatitis and PDAC (Crnogorac-Jurcevic et al., 
2001; 2002; Iacobuzio-Donahue et al., 2002; Logsdon et al., 2003; Iacobuzio-Donahue, 
Ashfaq, et al., 2003; Iacobuzio-Donahue, Maitra, et al., 2003; Crnogorac-Jurcevic et al., 
2003; Grützmann, Pilarsky, et al., 2004; Grützmann et al., 2005; Ishikawa et al., 2005; 
Segara et al., 2005; Lowe et al., 2007; Karanjawala et al., 2008). Only one study has looked 
at gene expression changes between PDAC of different stages (Kim et al., 2007). Ours was 
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the first, to our knowledge, to study molecular differences between nonmetastatic versus 
metastatic primary tumors and identify and validate a prognostic signature for PDAC. 
Of the six genes identified in this study, most do not have an obvious role in 
carcinogenesis. Three of the six genes demonstrated significantly higher expression in the 
poor prognostic groups (SIGLEC11, KLF6, NFKBIZ; Tables 8-9). ATP4A, GSG1, and 
SIGLEC-11 have not been studied in cancer. SIGLEC-11 is thought to be expressed by tissue 
macrophages and also the brain microglia (Angata et al., 2002). Interestingly, a missense 
mutation of SIGLEC-11 (S465A) was identified in the mutation discovery screen of the 
recent genome-wide sequencing of PDAC (S Jones et al., 2008). NFKBIZ, also called 
IkappaB zeta, binds to the p50 subunit of nuclear factor (NF)-kappaB and is important for 
interleukin-6 (IL-6) induction and may be induced by IL-1 receptor and Toll-like receptors 
(Angata et al., 2002). Given the prevalence of chronic pancreatitis and high degree of stromal 
fibrosis, it is possible that NFKBIZ may play a role in PDAC and inflammation. 
KLF6 is a transcription factor and its full-length transcript is thought to be a tumor 
suppressor gene involved in prostate, lung, and ovarian carcinogenesis (DiFeo et al., 2009). 
However a splice variant KLF6- SV1 has been shown to have oncogenic properties. The 
oligonucleotide probes used in the Agilent whole human genome array and the antibody 
against KLF6 did not differentiate between the full-length and splice variant. In agreement 
with a previous study (Hartel et al., 2008), we found that KLF6 protein expression was 
higher in tumors than normal pancreas. In addition we found that higher KLF6 expression 
was associated with worse survival. Hartel et al. further investigated KLF6-SV1 expression 
in their study using real-time PCR and demonstrated that the higher KLF6 expression seen in 
tissues was associated with a higher ratio of KLF6-SV1 compared to full-length KLF6. 
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Therefore our findings that KLF6 expression is higher in tumors and is prognostic is likely in 
agreement with this study. 
Only one patient in the UNC1 cohort was treated with neoadjuvant chemotherapy 
compared to 80% of NEB patients who were treated with palliative chemotherapy. Although 
there is a possibility that our signature may be reflective of gemcitabine treatment or perhaps 
resistance, as NEB patients died of metastatic disease despite gemcitabine treatment, the 
successful application of our six-gene signature on an independent test set of patients where 
only 3% of patients with localized PDAC were treated with neoadjuvant therapy suggests 
that it is a rigorous predictor of prognosis in previously untreated patients. We found no 
association between our six-gene signature and whether a patient received adjuvant 
chemotherapy. In addition, chemotherapy treatment in this cohort, either pre- or 
postoperative, did not demonstrate a survival advantage. 
Another concern is the validity of our hypothesis that gene expression changes at 
different stages of primary PDAC development may occur and be important for prognosis. 
Our study is in agreement with Lowe and colleagues’ findings that differential gene 
expression changes can be identified within primary PDAC (Kim et al., 2007). However, 
they did not address the prognostic value of their findings. Several studies have also 
suggested that gene expression changes in metastasis may be found in primary tumors. In a 
study of molecular differences between primary tumors and metastases, Golub and 
colleagues identified a gene expression signature of metastasis present that could be 
identified in primary tumors (Ramaswamy et al., 2003). In addition, studies in melanoma 
have suggested that metastatic cells may be found in the parent primary tumor (Fidler and 
Kripke, 1977). Finally studies in breast cancer have demonstrated that gene expression 
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changes found in breast cancer cells with metastatic potential may be prognostic and 
predictive of patients who will develop metastasis (Minn, Y Kang, et al., 2005; Minn, Gupta, 
et al., 2005; Minn et al., 2007). Our study is the first to demonstrate that molecular 
differences in metastatic PDAC can be identified at earlier stages, and that these differences 
are predictive of future behavior. Whether these molecular changes are biologically 
associated with metastatic potential will require further investigation. 
We have applied our six-gene signature to an independent dataset of 67 patients, and 
have validated its prognostic value. In addition, we have validated the protein expression of 
KLF6 in a 50-patient TMA. Although not nearly as powerful a predictor of prognosis as our 
six-gene signature, we found that KLF6 expression was prognostic in our 50-patient TMA. 
Further validation studies will be needed to see if KLF6 alone may be a useful prognostic 
marker as others have shown (Hartel et al., 2008). Our findings suggest that the prognostic 
value of KLF6 is strengthened in evaluating the six genes in their entirety. 
Studies of patients with resectable PDAC demonstrate median survivals of up to 22 
months, equivalent to the median survival of patients in our training and testing cohorts 
(Neoptolemos et al., 2001; Neuhaus et al., 2008; Ueno et al., 2009). Our finding that our six-
gene signature is able to stratify patients, with startling differences in survival, suggests that 
it may be used to select patients for therapies. For example, for patients who are at high 
operative risk, knowledge of a median survival of 49 compared to 15 months, may be helpful 
in the operative decision-making process. Similarly, patients who have a poor prognosis 
based on the six- gene signature may be considered for neoadjuvant therapy. Currently, the 
minority of centers use neoadjuvant therapy as a standard of care, most instead reserve this 
for patients with locally advanced unresectable or borderline resectable tumors. Therefore the 
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current decision-making process is based on anatomical considerations. Our prognostic 
signature may refine this paradigm such that neoadjuvant therapy is offered to patients on the 
basis of biological considerations, regardless of resectability, and may allow us to further 
study and maximize the benefits of neoadjuvant treatment. In addition, as new therapies are 
developed, it may help to determine whether patients may require more or less aggressive 
treatment. Finally, our findings that there are molecular differences associated with late-stage 
primary tumors, which translate into differences in prognosis, suggest that the six genes in 
this signature should be further studied for their potential as biomarkers, and some of these 
genes, or the pathways that they fall into, may represent new therapeutic targets. 
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Chapter III 
Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by 
inducing lethal chromosomal instability 
Overview 
Pancreatic ductal adenocarcinoma (PDAC), which accounts for the majority of 
pancreatic cancers, is a lethal disease with few therapeutic options. Genomic profiling of 
PDAC has identified a complex and heterogeneous landscape.  Further understanding of 
PDAC molecular biology will facilitate the identification of potential therapeutic strategies. 
We analyzed the gene expression profiles of primary tumors from patients compared to 
normal pancreas and identified high co-overexpression of core components of the spindle 
assembly checkpoint (SAC), including the protein kinase TTK. We found overexpression of 
TTK protein in a subset of PDAC primary tumors and cell lines. siRNA-mediated depletion 
or catalytic inhibition of TTK resulted in an aberrant cell cycle profile, multi- and micro-
nucleation, induction of apoptosis, and decreased cell proliferation and transformed growth. 
Selective catalytic inhibition of TTK caused override of the SAC-induced cell cycle arrest. 
Together these results suggest the importance of the role of TTK-dependent SAC activation 
to prevent excessive chromosomal instability and support growth. Unexpectedly, we 
identified ubiquitin specific peptidase 16 (Usp16), a ubiquitin hydrolase, as a 
phosphorylation substrate of TTK. Usp16 regulates chromosomal condensation and G2/M 
progression by deubiquitinating histone H2A. Phosphomimetic mutants of Usp16 show 
enhanced proteosomal degradation and may prolong the G2/M transition allowing for 
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correction of replication errors. Taken together, our results suggest a critical role for TTK in 
preventing aneuploidy-induced cell death in pancreatic cancer. 
Introduction 
PDAC represents 95% of all pancreatic cancers and is the fourth leading cause of 
cancer related deaths in the United States. Median survival of pancreatic cancer patients is 
five to eight months with fewer than 5% of patients surviving longer than five years after 
diagnosis. The poor prognosis stems from the frequent presence of metastatic disease at the 
time of or shortly after diagnosis. The current standard of care for metastatic pancreatic 
cancer is chemotherapy. Although chemotherapeutic approaches including gemcitabine, nab-
paclitaxel, and FOLFIRINOX have improved patient survival (Conroy et al., 2011; Gourgou-
Bourgade et al., 2013; Hoff et al., 2013), the discovery of new and better drugs targets 
remains essential for the continued improvement of therapies for PDAC.  
Genomic and mouse model studies have advanced our understanding of PDAC tumor 
biology and have identified a high degree of chromosomal instability in PDAC (Moskovitz et 
al., 2003; Hingorani et al., 2005; Gotoh et al., 2011).  One aspect of chromosomal instability 
is the unequal segregation of chromosomes during mitosis, resulting in aberrant 
chromosomal numbers and cellular aneuploidy of both daughter cells (Thompson and 
Compton, 2008). It has long been postulated that chromosomal instability is an important 
mechanism for tumor adaptation (Nowell, 1976; Lengauer et al., 1998). However, recent 
studies have hypothesized that the adaptive capacity of cancer cells to aneuploidy is limited 
(Birkbak et al., 2011; Tang et al., 2011). Aneuploid cancer cells must maintain a delicate 
balance between sustaining an altered genome that enhances proliferation yet confines 
continued chromosomal instability within survivable limits (Kops et al., 2004; Janssen et al., 
2009). As such, there is a pressing need to characterize the adaptive mechanisms that control 
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this balance to potentially identify therapeutic targets that can shift this balance from 
sustainable to non-viable chromosomal instability.   
 Chromosomal segregation during mitosis is a multi-step process and errors during 
this often result in aneuploidy (Gordon et al., 2012). Therefore, the timing of each step is 
tightly regulated in order to maintain mitotic fidelity. In normal cells, mitotic checkpoints 
ensure that each step is completed prior to continuing through the next phase of the cell 
cycle. The importance of these checkpoints in cancer is an area of current interest as 
inactivation of mitotic checkpoints has been shown to enhance chromosomal instability 
(Duijf and Benezra, 2013), which may result in aneuploidy and decreased cell fitness. 
The spindle assembly checkpoint (SAC) is a conserved mitotic checkpoint found 
from yeast to mammals that ensures accurate segregation of chromosomes during mitosis. 
During metaphase, sister chromatids congregate at the metaphase plate prior to separation 
during anaphase. The SAC is activated to prevent the premature onset of anaphase until bi-
oriented microtubule attachment at each kinetochore. Failure to activate the SAC has 
previously have been shown to promote chromosomal instability (Kops et al., 2004; 
Thompson and Compton, 2008; Rao et al., 2009; Janssen et al., 2009). 
SAC activation requires the expression and activity of the protein kinase TTK, also 
known as Mps1/Pyt/CT96, (X Liu and Winey, 2012). Overexpression of TTK has been 
proposed to be an adaptive mechanism whereby cells cope with aneuploidy. In agreement 
with this hypothesis, high levels of TTK mRNA have been observed in multiple cancer types 
and been shown to be protective against aneuploidy (Thykjaer et al., 2001; Yuan et al., 2006; 
Salvatore et al., 2007; Landi et al., 2008; Mizukami et al., 2008; Daniel et al., 2011; Maire et 
al., 2013). Previous studies have investigated the role of TTK in cancer using pharmacologic 
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inhibitors in cancer cell lines. Pharmacologic inhibition of TTK in colorectal and 
glioblastoma cancer cell lines reduced cell viability, caused aberrant cell cycle progression, 
increased aneuploidy, and increased apoptosis (Kwiatkowski et al., 2010; Tardif et al., 2011; 
Jemaà et al., 2013; Tannous et al., 2013). Similarly, a recent study provides a tantalizing 
rationale to look at the role of TTK overexpression in PDAC. This study found that 
pharmacologic inhibition of TTK in PDAC caused aberrant override of SAC-dependent cell 
cycle arrest, increased chromosomal instability, increased apoptosis and decreased 
clonogenic survival (Slee et al., 2014). While this study demonstrated that pharmacologic 
inhibition of TTK might prevent PDAC growth, several questions remain unanswered about 
the biological role of TTK in PDAC. First, although the pharmacologic inhibitor used was 
selective for TTK, it also inhibits casein kinase 2 (CK2), maternal embryonic leucine zipper 
kinase (MELK), and NIMA-related kinase 6 (NEK6) (Colombo et al., 2010). Second, TTK 
has a large N-terminal domain with protein binding motifs that may participate in disparate 
pathways and processes that support PDAC growth that cannot be directly studied using 
catalytic site ATP-competitive pharmacologic inhibitors. Third, Slee et al. focused on the 
effects of TTK inhibition of PDAC cell lines after several cell divisions and the acute role of 
TTK for PDAC growth remains undetermined. Finally, the requirement of TTK for cellular 
transformation and in vivo tumorigenesis in PDAC were not evaluated.   
Although this study clearly implicates the importance of TTK catalytic activity for 
continued PDAC cell line growth, how TTK promotes growth remains unclear, mainly 
because only few TTK phosphorylation substrates have been identified (Zhu et al., 2007; 
Jelluma, Brenkman, van den Broek, et al., 2008; Huang et al., 2009; Sun et al., 2010).  
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The overall goal of this study was to investigate the role of TTK in mitotic 
progression, proliferation and transformation of PDAC and identify the molecular 
mechanism whereby TTK limits chromosomal instability. We found increased mRNA 
expression of core SAC components and elevated mRNA and protein expression of TTK in a 
subset of PDAC cell lines and human tumors, suggesting that TTK might protect cells from 
excessive chromosomal instability through SAC activation. We also found that TTK 
phosphorylates and regulates the protein stability of Usp16, an enzyme required to promote 
chromosomal condensation, suggesting that TTK functions at multiple stages of the cell 
cycle to maintain genome stability. Together these findings establish the importance of TTK 
to adapt to and maintain viable levels of aneuploidy in PDAC. 
Experimental procedures: 
Tissue Collection  
Human tumor lysates from flash-frozen samples were homogenized in NP40 lysis 
buffer, resolved by SDS–PAGE, and evaluated by western blot analysis. 
RNA Microarray analysis  
Gene expression microarray data of 184 normal colon and primary pancreatic tumor 
samples from patients was obtained from the Gene Expression Omnibus (GEO) database 
(accession number GSE21501). Normalization, quality control, and imputation of array data 
was performed as previously described (Stratford et al., 2010).  Expression data from 
multiple probes were collapsed by the mean for each sample. Statistical significance was 
assessed using a two-tailed unpaired t-test comparing SAC component expression in normal 
versus tumor tissue. Differentially expressed genes were identified using statistical analysis 
of microarrays (SAM) using a 5% false discovery rate (FDR) (Tusher et al., 2001). Gene 
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networks were were investigated for enrichment of differentially expressed kinases using 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Mountain View, CA).  
Cell culture and reagents  
All cell lines except HPDE, HPNE, 293FT, HuPT3 were obtained from American 
Type Culture Collection (ATCC, LGC Promochem). The HPDE cell line was obtained from 
Ming-Sound Tsao (University of Toronto, Toronto). The HuPT3 cell line was obtained from 
Dan Billadeau (Mayo Clinic, Rochester, MN). 293FT cells were purchased from Invitrogen 
(Grand Island, NY). The HPNE cell line was obtained from Michel Ouellete (UNMC Eppley 
Cancer Center) and has been described previously (KM Lee et al., 2003; PM Campbell et al., 
2007). All cell lines were maintained at 37°C and 5% CO2. HPAC, PANC-1, MIA PaCa-2, 
T3M4, HPAF-II, HPNE, HPDE, 293T, 293FT, and HeLa cell lines were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, Corning). BxPC-3, Panc 02.03, Panc 10.05, 
AsPC-1, SW-1990, HuPT3, CFPAC-1, Capan-1 and Capan-2 cell lines were maintained in 
RPMI-1640 with 4.5g/L glucose.  All media was supplemented with 10% (vol/vol) fetal 
bovine serum (FBS, Hyclone), and 100 U/ml penicillin and 100 U/ml streptomycin (P/S, 
Gibco). Capan-1 cells which were supplemented with 15% (vol/vol) FBS.   
Antibodies 
Primary antibodies used for immunoblot or immunoprecipitation include: Mouse anti-
β-actin (IB, 1:5000, AC-15, Sigma Aldrich) mouse anti-TTK (IB, 1:2000, 4-112-3 Millipore) 
rabbit anti-Cyclin B1 (IB, 1:1000, 4138 Cell Signaling), rabbit anti-Histone H3 phospho Ser 
10 (IB, 1:1000, 9701 Cell Signaling), mouse anti-FLAG (IB, 1:1000, M2 Sigma Aldrich), 
mouse anti-phospho tyrosine (IB, 1:1000, 9411 Cell Signaling), mouse anti-phospho serine 
(IB, 1:1000, 4A4 Millipore), mouse anti-phospho threonine (IB, 1:1000, Cell Signaling 3986) 
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rabbit anti-Usp16 (IB, 1:2000, Bethyl A301-615A) mouse anti-HA (1:1000, Covance 
16B12), and mouse anti-GFP (1:5000 Clontech JL8). HRP conjugated secondary antibodies 
include goat anti-mouse (1:10000, Thermo) or goat anti-rabbit (1:10000, Thermo). 
Immunoprecipitation and immunoblotting  
Two to five micrograms of specified antibodies were bound to 20-50 µl of Protein G 
Dynabeads (Invitrogen) overnight at 4°C. Cells were collected following treatments as 
specified in the figure legends. Cells were harvested and then lysed in NP-40 lysis buffer (50 
mM Tris pH 7.5, 10 mM MgCl2, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 
and 10% glycerol) supplemented with phosphatase (Roche) and protease (Sigma) inhibitor 
cocktails. Cell lysates were incubated with antibody bound Dynabeads overnight at 4°C. 
Beads were washed three times with lysis buffer and resuspended in protein sample buffer 
containing β-mercaptoethanol and examined by immunoblotting. 
Immunoblots were performed by running protein samples on either 15% (for proteins 
under 40 kDa) or 8% SDS-PAGE followed by transfer of resolved proteins to PVDF 
membranes for 90 min at 4°C. All immunoblots were blocked in 5% milk/TBST solution for 
1 h at room temp with gentle agitation. Primary antibodies were diluted in 5% (weight/vol) 
milk or 5% BSA. Primary antibodies were incubated overnight at 4°C.  Following incubation 
with primary antibody blots were washed 3x with TBST and then incubated with secondary 
HRP-conjugated antibodies for 1 h at room temp with gentle agitation. Blots were again 
washed 3x with TBST and developed by ECL/chemiluminescence and auto-radiograph film 
(Kodak) or the Biorad XRS+ imaging system. 
FLAG pull-down were performed on cell lysates using the pull-down buffer (50 mM 
Tris pH 7.6, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM 
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EGTA) and supplemented with protease inhibitors (Roche). Lysates were clarified by 
centrifugation. 10 mg of protein were used in each pull down. Anti-FLAG M2 magnetic 
beads (Sigma) were used to immunoprecipitate FLAG-tagged Usp16. Following extensive 
washing with TBS, FLAG-Usp16 was eluted with FLAG peptide (Sigma) in TBS. 
cDNA expression  
Expression vectors for firefly luciferase (plasmid #17477), FLAG-HA-Usp16 
(Plasmid #22595) were obtained from Addgene. GFP-Usp16 was prepared by amplifying 
Usp16 cDNA from FLAG-HA-Usp16 followed by subcloning into pEGFP-C3 using the 
XhoI  and BamHI sites. GFP-Usp16 3xA and 3xE were prepared by site-directed 
mutagenesis and confirmed by sequencing.  
 Transfections for all cDNA were accomplished using a HBS/CaCl2 or TransIT-LT1 
(Mirius Bio) protocol and cells were examined for expression 48-72 h post transfection  
siRNA transfection  
All siRNA described were obtained from Thermo and are part of their ON-
TARGETplus SMARTpools of siRNA. siRNAs were transfected using RNAiMax 
(Invitrogen).  
Cell proliferation assays 
For the MTT proliferation assay, 300 x 103 cells were transfected with siRNA using 
RNAiMax transfection reagent. Forty-eight hours post transfection 1 x 103 cells were plated 
into 6 identical wells of a 96-well plate. Proliferation was assessed by addition of the MTT 
reagent for 4 h. Measurements were taken at an A560 on the Synergy 2 (Biotek).  
For the soft agar assay, 104 siRNA transfected cells were suspended between layers of 
0.6% (bottom) and 0.3% (top) bacto-agar (BD Biosciences) in three wells of a 6-well dish. 
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Cells were supplied with growth medium twice a week and allowed to form colonies for 7-28 
days. Colonies were visualized by staining with MTT (2 mg/ml). Colonies were imaged and 
quantitated using ImageJ (National Institute of Health).  
Cell cycle analysis by flow cytometry  
DNA content was assayed using propidium iodide. Cells were harvested, washed and 
fixed in 70% ethanol. Cells were permeabolized with 0.5% Triton X-100 and stained with 
propidium iodide. Stained cells were quantitated on the CyAN flow cytometer (Beckman 
Coulter). Distribution of cells in each stage of the cell cycle was performed using ModFit 
(Verity Software House).  
Immunofluorescence  
PANC-1 and HPAC cells were plated on poly-L-lysine (Sigma) coated coverslips. 
Cells were fixed in 4% paraformaldehyde, permeabolized with 0.2% Triton X-100. Cells 
were then blocked in 5% BSA in PBS. Cells were allowed to stain for 2 h at room 
temperature, washed three times with PBS. Alexa Fluor-conjugated secondary antibodies 
(Invitrogen) and DAPI were allowed to bind for 1 h. Stained cells were washed three times 
with PBS, followed by one wash with distilled water. Coverslips were then mounted with 
Fluorsave (Calbiochem).  
All confocal images were obtained on a Zeiss 710 spectral confocal laser scanning 
confocal microscope equipped with a 405, 458, 488, 514, 543, 594, 633 nm excitation lines. 
Images were obtained using a 40X or 63X oil plan/Apo objective. Multicolor images were 
acquired using sequential scanning. All images were visualized using ImageJ and cropped 
using Photoshop.  
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Apoptosis Evaluation  
Apoptosis was evaluated using an Annexin V assay (Roche) following 
manufacturer’s protocol. Live cells were harvested in Tryp-LE (Gibco), washed in PBS, 
incubated in binding buffer with FITC conjugated Annexin V. Necrotic cells were 
discriminated by using a propidium iodide counterstain. Stained cells were quantitated on the 
CyAN flow cytometer (Beckman Coulter). At least 10,000 events were analyzed for each 
sample.  
P32 incorporation assay 
Kinase assays were performed using recombinant active GST-Tagged TTK 
(SignalChem). FLAG-Usp16 was purified from 293FT cells stably expressing FLAG-Usp16. 
Kinase assay was performed at 30°C for 15 and 30 min in 50 µl assay buffer (5 mM MOPS 
pH 7.2, 2.5 mM beta glycerol phosphate, 5 mM MgCl2, 1 mM EGTA, 0.4 mM  EDTA, 200 
µM ATP, 0.4 mCi/ml  [ϒ-32P]ATP, 50 µM DTT, 50 ng/µl BSA). Five microliters of the 
reaction was spotted onto Whatman P81 cellulose phosphate filter paper. Reactions were 
quenched by washing the filter paper with 10% phosphoric acid three times for 5-10 min 
each. Filter paper was washed once with ethanol and dried. Filter papers were placed into 
scintillation vials, scintillation fluid was added to each vial, and P32 incorporation was 
assessed on the Beckman LS6500. 
Results:  
High expression of spindle assembly checkpoint kinases identified in PDAC 
Protein kinases are the most frequently mutated family of genes that promote cancer 
and are therefore an attractive class of highly druggable molecular targets (Lahiry et al., 
2010). However, mutations in protein kinases are relatively uncommon in PDAC (17.6%) 
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compared to breast (75%), lung (86%), and colon (93%) cancers (S Jones et al., 2008; 
Biankin et al., 2012; Cancer Genome Atlas Network, 2012; Koboldt et al., 2012) 
(https://tcga-data.nci.nih.gov/). Gene amplifications and overexpression of protein kinases 
has also been shown to promote oncogenesis (Chou et al., 2013). Thus we examined what 
protein kinases were overexpressed in PDAC by analyzing gene expression profiles of 
previously published cDNA microarrays of primary PDAC tumors (n=30) and normal 
pancreas (n=20) (Stratford et al., 2010). We identified differentially expressed kinases using 
the Statistical Analysis of Microarrays (SAM) software (Tusher et al., 2001; YH Yang et al., 
2002). Of 3899 differentially expressed genes between primary patient tumors and normal 
pancreas, 106 probes were representing 91 kinases were identified (Table 10). 
We identified biological networks regulated by the differentially expressed kinases 
using IPA. We found that the cell cycle was one of the most enriched biological pathways 
regulated by our list of kinases in PDAC (Table 11, Figure 12A, 13), with 7 of the 10 most 
upregulated kinases (Table 12). Interestingly, three of these seven kinases are involved with 
the spindle assembly checkpoint (SAC): BUB1, BUB1B, and TTK. Further interrogation of 
the gene expression profiles found statistically significant co-overexpression of both kinase 
and non-kinase components of the SAC in PDAC tumors compared to normal pancreas 
(Figure 12B). Together these data suggests that the SAC may be important for mitotic 
fidelity in PDAC. 
TTK kinase activity is essential to activate the SAC and prevent early anaphase onset 
(Hardwick et al., 1996; Bettencourt-Dias et al., 2004; MH Jones et al., 2005; May and 
Hardwick, 2006). In order to evaluate the role of TTK we evaluated the expression of TTK at 
the protein level and confirmed that a subset of primary PDAC patient samples had elevated 
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TTK protein expression compared to normal pancreas tissue (Figure 12C). In addition, we 
evaluated TTK protein expression in a panel of 14 PDAC cell lines by immunoblot analysis 
(Figure 12D). We selected two cell lines with moderate TTK expression, HPAC and PANC-
1, to conduct our studies.  
TTK is necessary for PDAC growth 
To determine the functional consequence of TTK expression on PDAC growth we 
depleted TTK in PANC-1 and HPAC cell lines using a pool of 5 individually targeted 
siRNAs (Figure 14). TTK protein knockdown was confirmed by immunoblot analysis 
(Figure 15A). HPAC and PANC-1 cells depleted of TTK showed a significant decrease in 
proliferation as determined by the thiazolyl blue tetrazolium bromide (MTT) assay (Figure 
15B). Catalytic inhibition of TTK with AZ3146 (AstraZeneca) phenocopied the decrease in 
proliferation seen with siRNA in HPAC and PANC-1 cells (Figure 15C). We next examined 
the requirement for TTK to support PDAC transformed growth by measuring anchorage-
independent colony formation in soft agar, a standard assay for cellular transformation. 
Genetic depletion or catalytic inhibition of TTK in PANC-1 and HPAC cell lines 
significantly decreased transformed growth of the cells (Figure 15 D-F).  
 
Override of the spindle assembly checkpoint and aberrant cell cycle progression and 
mitotic aberrancies and apoptosis 
It is well established that TTK is required for proper SAC activation and function (X Liu and 
Winey, 2012). To understand the molecular mechanism whereby TTK supports PDAC 
growth we investigated the effects of TTK inhibition on SAC activation. HPAC and PANC-1 
cells were arrested in mitosis with 100 ng/ml nocodazole and then challenged with 
Table 10. Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-change values 
and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_23_P201988 MASTL microtubule associated serine/threonine kinase-like 1.75 0.53 
AGI_HUM1_OLIGO_A_23_P20248 MAP2K1 mitogen-activated protein kinase kinase 1 1.42 2.49 
AGI_HUM1_OLIGO_A_23_P207896 CSNK1D casein kinase 1, delta 1.38 2.02 
AGI_HUM1_OLIGO_A_23_P213114 TEC tec protein tyrosine kinase 1.33 4.20 
AGI_HUM1_OLIGO_A_23_P215461 LIMK1 LIM domain kinase 1 1.54 1.43 
AGI_HUM1_OLIGO_A_23_P216920 NEK6 NIMA (never in mitosis gene a)-related kinase 6 1.31 5.07 
AGI_HUM1_OLIGO_A_23_P24997 CDK4 cyclin-dependent kinase 4 1.33 2.93 
AGI_HUM1_OLIGO_A_23_P251342 GSK3B glycogen synthase kinase 3 beta 1.32 0.39 
AGI_HUM1_OLIGO_A_23_P252106 RIPK2 receptor-interacting serine-threonine kinase 2 1.35 2.93 
AGI_HUM1_OLIGO_A_23_P256312 MST1R macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 2.00 0.13 
AGI_HUM1_OLIGO_A_23_P259586 TTK TTK protein kinase 2.97 0.00 
AGI_HUM1_OLIGO_A_23_P3204 MAPK6 mitogen-activated protein kinase 6 1.41 2.93 
AGI_HUM1_OLIGO_A_23_P342067 UHMK1 U2AF homology motif (UHM) kinase 1 1.36 2.02 
AGI_HUM1_OLIGO_A_23_P35219 NEK2 NIMA (never in mitosis gene a)-related kinase 2 3.42 0.00 
AGI_HUM1_OLIGO_A_24_P166663 CDK6 cyclin-dependent kinase 6 1.66 1.43 
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Table 10 (continued). Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-
change values and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_23_P359245 MET met proto-oncogene (hepatocyte growth factor receptor) 2.38 0.00 
AGI_HUM1_OLIGO_A_23_P39684 TLK1 tousled-like kinase 1 1.29 2.49 
AGI_HUM1_OLIGO_A_23_P397341 PKMYT1 progestin and adipoQ receptor family member IV 1.79 0.00 
AGI_HUM1_OLIGO_A_23_P418413 OXSR1 oxidative-stress responsive 1 1.33 1.12 
AGI_HUM1_OLIGO_A_23_P42784 STK31 serine/threonine kinase 31 1.91 2.93 
AGI_HUM1_OLIGO_A_23_P51646 PLK3 polo-like kinase 3 (Drosophila)|Tctex2 beta 1.57 5.07 
AGI_HUM1_OLIGO_A_23_P55578 RIOK3 RIO kinase 3 (yeast) 1.48 2.49 
AGI_HUM1_OLIGO_A_23_P55584 RIOK3 RIO kinase 3 (yeast) 1.53 1.77 
AGI_HUM1_OLIGO_A_23_P56978 PTK6 PTK6 protein tyrosine kinase 6 3.21 0.00 
AGI_HUM1_OLIGO_A_23_P57667 PLXNA1 plexin A1 1.71 0.00 
AGI_HUM1_OLIGO_A_23_P66732 GSG2 germ cell associated 2 (haspin) 1.44 2.49 
AGI_HUM1_OLIGO_A_23_P75989 PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 1.49 2.02 
AGI_HUM1_OLIGO_A_23_P76731 RAGE renal tumor antigen 1.52 2.02 
AGI_HUM1_OLIGO_A_23_P94422 MELK maternal embryonic leucine zipper kinase 1.80 0.53 
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Table 10 (continued). Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-
change values and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_24_P251899 CSNK1A1 casein kinase 1, alpha 1 1.30 3.47 
AGI_HUM1_OLIGO_A_24_P313504 PLK1 endoplasmic reticulum to nucleus signaling 2|polo-like kinase 1 (Drosophila) 1.52 2.02 
AGI_HUM1_OLIGO_A_24_P319613 NEK2 NIMA (never in mitosis gene a)-related kinase 2 2.14 0.00 
AGI_HUM1_OLIGO_A_24_P333663 MAPK6 mitogen-activated protein kinase 6 1.45 3.47 
AGI_HUM1_OLIGO_A_24_P37441 PDK1 pyruvate dehydrogenase kinase, isozyme 1 1.76 0.53 
AGI_HUM1_OLIGO_A_24_P42603 TRIO triple functional domain (PTPRF interacting) 1.43 5.07 
AGI_HUM1_OLIGO_A_24_P830690 PDPK1 3-phosphoinositide dependent protein kinase-1 1.36 4.20 
AGI_HUM1_OLIGO_A_24_P94054 STK4 serine/threonine kinase 4 1.51 4.20 
AGI_HUM1_OLIGO_A_32_P140501 AXL AXL receptor tyrosine kinase 1.49 5.07 
AGI_HUM1_OLIGO_A_32_P25204 PRKDC similar to protein kinase, DNA-activated, catalytic polypeptide 1.35 3.47 
AGI_HUM1_OLIGO_A_32_P62997 PBK PDZ binding kinase 2.76 0.00 
AGI_HUM1_OLIGO_A_32_P119174 IPPK inositol 1,3,4,5,6-pentakisphosphate 2-kinase|centromere protein P 1.37 5.07 
AGI_HUM1_OLIGO_A_24_P245646 TP53RK TP53 regulating kinase 1.30 3.47 
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Table 10 (continued). Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-
change values and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_24_P76319 LOC642609 similar to tau tubulin kinase 2 1.44 5.07 
AGI_HUM1_OLIGO_A_23_P10559 AATK apoptosis-associated tyrosine kinase -1.98 1.77 
AGI_HUM1_OLIGO_A_23_P110791 CSF1R 
colony stimulating factor 1 receptor, formerly 
McDonough feline sarcoma viral (v-fms) 
oncogene homolog 
-1.89 4.20 
AGI_HUM1_OLIGO_A_23_P125596 RPS6KA6 ribosomal protein S6 kinase, 90kDa, polypeptide 6 -1.28 4.20 
AGI_HUM1_OLIGO_A_23_P126416 TIE1 tyrosine kinase with immunoglobulin-like and EGF-like domains 1 -1.73 1.43 
AGI_HUM1_OLIGO_A_23_P128447 LRRK2 leucine-rich repeat kinase 2 -1.64 0.22 
AGI_HUM1_OLIGO_A_23_P134125 MAP3K5 mitogen-activated protein kinase kinase kinase 5 -1.41 3.47 
AGI_HUM1_OLIGO_A_23_P142304 MKNK2 MAP kinase interacting serine/threonine kinase 2 -1.74 2.93 
AGI_HUM1_OLIGO_A_23_P142310 MKNK2 MAP kinase interacting serine/threonine kinase 2 -1.61 2.02 
AGI_HUM1_OLIGO_A_23_P147711 NPR1 natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) -1.75 0.14 
AGI_HUM1_OLIGO_A_23_P159169 AATK apoptosis-associated tyrosine kinase -1.29 3.47 
AGI_HUM1_OLIGO_A_23_P164057 MAPK7 microfibrillar-associated protein 4|mitogen-activated protein kinase 7 -2.40 0.53 
AGI_HUM1_OLIGO_A_23_P16817 CLK1 CDC-like kinase 1 -1.67 1.12 
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Table 10 (continued). Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-
change values and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_23_P202245 RET ret proto-oncogene -1.46 5.07 
AGI_HUM1_OLIGO_A_23_P169819 EPHA3 EPH receptor A3 -1.87 2.02 
AGI_HUM1_OLIGO_A_23_P205900 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 -1.91 0.27 
AGI_HUM1_OLIGO_A_23_P207517 PDK2 pyruvate dehydrogenase kinase, isozyme 2 -1.36 1.77 
AGI_HUM1_OLIGO_A_23_P211985 SNRK SNF related kinase -1.60 1.77 
AGI_HUM1_OLIGO_A_23_P219105 FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) -1.46 3.47 
AGI_HUM1_OLIGO_A_23_P253602 BMX BMX non-receptor tyrosine kinase -1.81 1.12 
AGI_HUM1_OLIGO_A_23_P300033 PDGFRA platelet-derived growth factor receptor, alpha polypeptide -2.04 2.02 
AGI_HUM1_OLIGO_A_23_P301304 FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) -1.75 1.43 
AGI_HUM1_OLIGO_A_23_P34804 NTRK1 neurotrophic tyrosine kinase, receptor, type 1 -1.55 4.20 
AGI_HUM1_OLIGO_A_23_P372923 FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) -1.47 5.07 
AGI_HUM1_OLIGO_A_23_P374695 TEK TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal) -2.89 0.00 
AGI_HUM1_OLIGO_A_23_P397455 ACVR1C activin A receptor, type IC -1.67 5.07 
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Table 10 (continued). Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-
change values and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_23_P46618 PLXNA2 plexin A2 -1.94 3.47 
AGI_HUM1_OLIGO_A_23_P55107 ULK2 unc-51-like kinase 2 (C. elegans) -1.82 0.27 
AGI_HUM1_OLIGO_A_23_P424 MARK1 MAP/microtubule affinity-regulating kinase 1 -1.64 2.02 
AGI_HUM1_OLIGO_A_23_P61674 CLK4 CDC-like kinase 4 -1.56 2.02 
AGI_HUM1_OLIGO_A_23_P84974 NRK Nik related kinase -2.27 3.47 
AGI_HUM1_OLIGO_A_24_P106112 PKD2 polycystic kidney disease 2 (autosomal dominant) -1.41 4.20 
AGI_HUM1_OLIGO_A_24_P179585 MARK1 MAP/microtubule affinity-regulating kinase 1 -1.47 4.20 
AGI_HUM1_OLIGO_A_24_P243749 PDK4 pyruvate dehydrogenase kinase, isozyme 4 -3.69 0.00 
AGI_HUM1_OLIGO_A_24_P263144 BMX BMX non-receptor tyrosine kinase -1.98 0.22 
AGI_HUM1_OLIGO_A_24_P319923 MYLK myosin, light chain kinase -2.25 4.20 
AGI_HUM1_OLIGO_A_24_P4171 FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) -1.39 4.20 
AGI_HUM1_OLIGO_A_24_P71973 KDR kinase insert domain receptor (a type III receptor tyrosine kinase) -1.68 1.77 
AGI_HUM1_OLIGO_A_32_P100379 PDGFRA platelet-derived growth factor receptor, alpha polypeptide -1.79 0.39 
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Table 10 (continued). Overexpressed protein kinases in primary PDAC compared to normal pancreas, with their respective fold-
change values and false discovery rates. 
Gene ID Gene Name Gene Product Fold Change q-value(%) 
AGI_HUM1_OLIGO_A_32_P105865 ROCK1 Rho-associated, coiled-coil containing protein kinase 1 -1.60 5.07 
AGI_HUM1_OLIGO_A_32_P183765 ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) -2.13 3.47 
AGI_HUM1_OLIGO_A_32_P200586 CLK1 CDC-like kinase 1 -1.37 3.47 
AGI_HUM1_OLIGO_A_32_P94160 PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit -1.60 2.49 
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Table 11. Biological pathways enriched with differentially expressed 
kinases. 
Network name p-Value # of nodes 
Post-translational modification 1.14E-67 – 3.85E-04 66 
Cell cycle 6.76E-24 – 4.16E-04 43 
Amino acid metabolism 1.46E-19 -1.45E-08 18 
Small molecule biochemistry 1.46E-19 – 2.42E-06 25 
Cell death and survival 5.53E-19 – 4.16E-01 58 
Table 12. Function of the 10 most overexpressed kinases 
Kinase Fold Change FDR (Q-Value) Function 
BUB1 3.887 0 Cell cycle 
NEK2 3.424 0 Cell cycle 
CHEK1 3.362 0 Cell cycle 
PTK6 3.213 0 Differentiation and apoptosis 
TTK 2.972 0 Cell cycle 
PBK 2.756 0 Cell cycle 
STYK1 2.65 0.125 Proliferation and survival 
MET 2.381 0 Growth factor sensing 
CDK1 2.343 0 Cell cycle 
BUB1B 2.114 0 Cell cycle 
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Figure 12. Increased expression spindle assembly checkpoint components and its 
regulator TTK in PDAC. (A) Ingenuity Pathway Analysis software identified prominent 
cellular functions that were significantly affected by differentially expressed kinases between 
normal and primary PDAC. (B) Box and whisker plot of median, upper, and lower quartiles 
of mRNA expression of core components and regulators of the spindle assembly checkpoint. 
Asterisk represent the p-value of the Mann-Whitney test (ns: p≥0.05, **: p≤0.01, ***: 
p≤0.001, ****: p≤0.0001). (C) Expression of TTK in a panel of patient samples. N = normal 
pancreas and T = primary tumor. (D) Expression of TTK in immortalized pancreas 
epithelium (HPNE and HPDE) and PDAC cell lines. 
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Figure 13. Ingenuity pathway analysis of differentially expressed kinases in primary 
PDAC compared to normal pancreas identified by unbiased methods. All 106 
differentially regulated kinases were analyzed by integrated pathway analysis using 
Ingenuity.  The posttranslational modification cell cycle, cellular assembly and organization, 
one of the most dominant networks, is depicted here. Signaling pathways are colored 
according to expression, green representing downregulation and red representing 
upregulation with the expression fold change represented by more intense colors.  
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2 µM AZ3146. We monitored the stability of the mitotic marker cyclin B to assess silencing 
of the SAC. Catalytic inhibition of TTK caused a drop in the levels of cyclin B (Figure 16A), 
indicating that the catalytic inhibition of TTK caused an escape from checkpoint mediated 
mitotic arrest and accelerated mitotic progression. We next investigated the effect of 
checkpoint silencing on cell cycle progression. We determined the cell cycle phase 
distribution of HPAC and PANC-1 cells treated with siRNA or AZ3146 after 72 h by 
propidium iodide staining and flow cytometry analysis. Aberrant distribution of cells in each 
cell cycle phase occurred, specifically an increase post G2 cells, indicative of multi-
nucleation (Figure 16B-C). 
TTK is required to prevent aneuploidy and apoptosis 
Studies in other tumors have found that TTK depletion causes premature mitotic progression 
and often results in aberrant chromosomal segregation and aneuploidy (Fisk et al., 2003; 
Tighe et al., 2008; Tannous et al., 2013). In PDAC, TTK inhibition induced gains in the X 
chromosome and chromosome 17. However, the effect of TTK inhibition on the nuclear 
architecture is unknown. We examined the nuclear architecture of PANC-1 cells stably 
transduced with a lenti-viral vector encoding H2B-GFP followed by depletion of TTK using 
siRNA. Fluorescent microscopy revealed gross multi- and micro-nucleation in TTK depleted 
cell lines compared to mismatch siRNA controls, which reflected widespread chromosomal 
segregation defects (Figure 16D-E). These results demonstrate the requirement of TTK for 
mitotic fidelity and that depletion of TTK results in an increase of chromosomal instability 
and aneuploidy.  
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Figure 14. Individual targeting of TTK of each siRNA used in the pool. Immunoblot 
analysis of HPAC and PANC-1 cell lines 48 h after transfection with 10 nM siRNA targeting 
TTK.
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Figure 15. Genetic and pharmacologic inhibition of TTK decrease growth of PDAC cell 
lines. (A) Immunoblot analysis of HPAC and PANC-1 cell extracts showing protein level of 
TTK in control mismatch siRNA (siMM) and a TTK siRNA (siTTK) pool 48 h after 
transfection. (B) Growth of HPAC and PANC-1 PDAC cell lines transfected with control 
siMM and siTTK show reduced proliferation with TTK depletion. Cells were measured for 
proliferation at 48, 72, and 120 h as indicated. (C) Growth of HPAC and PANC-1 PDAC cell 
lines treated with DMSO control or 2 µM AZ3146. Cells were measured for proliferation at 
48, 72, and 120 h as indicated. (D) Representative images of colony formation of the PANC-
1 cell line in soft agar. (E) Quantitation of colony formation in soft agar of the HPAC and 
PANC-1 cell lines after transfection of either control or TTK targeted siRNA. Samples 
normalized to control. (F) Quantitation of colony formation in soft agar of the HPAC and 
PANC-1 cell lines after with continuous treatment with vehicle (DMSO) or AZ3146. 
Normalized to DMSO control. Asterisk represent the P-value of the two sided T-test (ns: 
P≥0.05,*:≤0.05, P **: P≤0.01, ***: P≤0.001, ****: P≤0.0001). Results representative of at 
least 2 experiments. 
 
 
	   80	  
Unstable aneuploidy is often associated with cell death from mitotic catastrophe. To 
assess whether TTK is important to preventing apoptosis in PDAC cell lines, we monitored 
apoptotic induction by flow cytometry. siRNA mediated TTK depletion in PANC-1 cells 
resulted in increased Annexin V staining. However, at the same time point, catalytic 
inhibition of TTK did not promote apoptosis (Figure 16F-G).  
Usp16 is a direct substrate of TTK 
TTK has been shown to regulate mitotic progression by phosphorylation of mitotic 
regulators (Leng et al., 2006; Jelluma, Brenkman, van den Broek, et al., 2008). However, 
substrates of TTK that mediate mitotic progression require further characterization. To 
further delineate the molecular mechanism whereby TTK regulates proper mitotic 
progression necessary for growth we sought to identify phosphorylation substrates of TTK. 
To identify putative substrates of TTK we used the Scansite3 (http://scansite.mit.edu/) 
prediction software with an input phosphorylation consensus motif recently identified by 
Hennrich et al (Hennrich et al., 2013). This motif consists of a threonine residue with acidic 
amino acids in the −2, and/or −3 positions and hydrophobic branched-chain amino acids 
(leucine, valine and isoleucine) in the +2 and +3 position (Hennrich et al., 2013). Using this 
approach we identified 410 putative TTK phosphorylation substrates in humans. We focused 
on phosphorylation substrates with known roles in mitotic networks (Table 12) and 
identifiedthe ubiquitin specific peptidase 16 (Usp16, also known as Ubp-M) as a putative 
phosphorylation substrate of TTK. 
To examine if Usp16 is a direct phosphorylation substrate of TTK we performed an in 
vitro kinase assay with ADP-P32 and measured substrate incorporation of P32. Incorporation 
of P32 on purified Usp16 was enhanced when incubated with active TTK (SignalChem) and 
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inhibited upon addition of 2 µM AZ3146 (Figure 17A). These results indicate that Usp16 is 
directly phosphorylated by TTK in vitro. We next sought to identify the TTK dependent 
phosphorylation sites on Usp16 by performing mass spectrometry. TTK activity was 
stimulated with nocodazole in 293FT cells exogenously expressing a flag-tagged Usp16. 
Cells were then concurrently challenged with DMSO control or 2 µM AZ3146 for 4 h. 
FLAG-Usp16 from the cell lysate was purified by immunoprecipitation, digested with 
trypsin, and enriched for phosphopeptides. Amino acid composition of phosphopeptides was 
then identified by orbi-trap mass spectrometry. Analysis of the resulting spectra identified 
three TTK-dependent phosphorylation sites within Usp16: S415, S552, T554 (Figure 17B). 
TTK dependent phosphorylation of Usp16 causes protein degradation 
To investigate the importance of phosphorylation of these three residues on Usp16 function 
we created a green fluorescent protein (GFP) tagged phospho-mimetic mutant of Usp16 
where glutamic acid residues were substituted for the three identified phosphorylation sites 
(GFP-Usp16 3xE), and a phospho-deficient mutant of Usp16 where alanine residues were 
substituted for the three identified phosphorylation sites (GFP-Usp16-3xA). Immunoblot 
analysis of 293FT cells transfected with cDNA for wild type and mutant Usp16 revealed 
decreased expression of the phospho-mimetic mutant of Usp16. RT-PCR with Usp16 specific 
primers confirmed equivalent mRNA expression, suggesting that Usp16 phosphorylation 
promotes protein degradation. Inhibition of the proteasome with 10 µM MG-132 restored 
expression of the phosphomimetic Usp16 mutant (Figure 17C-E). Taken together, these data 
suggest that Usp16 is a phosphorylation substrate of TTK and that Usp16 phosphorylation on 
S415, S552, or S554 leads to proteasome degradation of Usp16. Discussion: 
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Figure 16. TTK inhibition overrides the SAC mediated cell cycle arrest and leads to 
aberrant cell cycle progression, multi-nucleation and apoptosis. (A) Immunoblot of 
HPAC and PANC-1 PDAC cell lines arrested in mitosis by treatment with nocodazole. Cells 
were then treated with 2 µM AZ3146 for 4 h and probed for expression of cyclin B1. (B) 
Representative flow cytometry plots of the cell cycle of HPAC and PANC-1 cell lines of 2 
experiments. Cells were transfected with control or TTK targeted siRNA. 72 h post 
transfection cells were fixed and stained with propidium iodide. DNA content was assessed 
by flow cytometry. (C) Quantitation of B showing distribution of cells in each phase of the 
cell cycle. (D) Confocal microscopy of the PANC-1 cell line stably expressing a GFP-
Histone 2B construct to visualize DNA. Chromosomal instability is visible in cells depleted 
of TTK in the form of multi- and micro-nucleation. (E) Quantitation of cells with multi- or 
micro-nucleated phenotypes. (F) Scatterplots showing induction of apoptosis with depletion 
of TTK. PANC-1 cells were transfected with control or a TTK targeted siRNA pool. 72 h 
post transfection cells were harvested and stained with the apoptotic marker Annexin V and 
the counterstained with propidium iodide to visualize necrotic cells. (G) quantitation of the 
apoptotic induction of cells used in F. 
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Figure 17. Usp16 is a TTK phosphorylation substrate. (A) In vitro kinase assay measuring 
TTK dependent phosphorylation by p32 incorporation measured by liquid scintillation 
counts. Representative of 2 independent experiments. (B) Exogenously expressed FLAG-
Usp16 was immunoprecipitated from DMSO and AZ3146 treated mitotic 293FT cells, 
digested with trypsin and enriched for phosphopeptides. Phosphorylated residues of Usp16 
were identified by mass spectrometry. Spectral counts of representative of individual 
experiments are shown. (C) Immunoblot analysis of 293FT cells transiently transfected with 
control GFP, GFP-Usp16, GFP-Usp16 3xA (phosphodeficient mutant) or GFP-Usp16 3xE 
(phosphomimetic mutant) and treated with control DMSO or MG-132. (D) Densitometry of 
(C). (E) RT-PCR of Usp16 using 2 independent taqman probes from cells used in from (C) 
normalized to β-actin and represented as percent of WT-Usp16.  
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Patients with PDAC have limited therapeutic options. Discovery of new and better 
drug targets is essential for the continued advancement of better therapies. Chromosomal 
instability and aneuploidy are characteristics of PDAC (Schreiner et al., 2003; Aguirre et al., 
2004; Heidenblad, 2004; Hingorani et al., 2005; Hezel et al., 2006; Bardeesy et al., 2006). 
The SAC limits chromosomal instability by ensuring faithful segregation of sister 
chromatids. Here we show RNA overexpression of the core components of the SAC in 
primary PDAC tumors compared to normal pancreas. We hypothesize that targeting the SAC 
function may alter the ability of cancer cells to adapt to aneuploidy and may be a possible 
therapy for PDAC. 
TTK is a protein kinase required for SAC activation and was overexpressed in our 
dataset (X Liu and Winey, 2012). TTK was a gene previously identified in a 25-gene 
signature associated with chromosomal instability and aneuploidy in cancer (Carter et al., 
2006). Thus, overexpression of TTK may represent an adaptive mechanism to sustain the 
growth of chromosomally unstable tumors. In support of this hypothesis, overexpression of 
TTK has been previously observed in multiple tumor types including PDAC (Slee et al., 
2014), breast (Yuan et al., 2006; Daniel et al., 2011; Maire et al., 2013; Al-Ejeh et al., 2014), 
bladder (Thykjaer et al., 2001), esophagus (Mizukami et al., 2008), lung (Landi et al., 2008), 
anaplastic thyroid (Salvatore et al., 2007), and glioblastoma (Tannous et al., 2013).  
To investigate the role of TTK as an adaptive response to aneuploidy in PDAC we 
investigated the effect of both catalytic and genetic depletion of TTK on mitotic progression.  
In agreement with a previous study we show that catalytic inhibition of TTK caused an 
aberrant override of the SAC mediated cell cycle arrest in PDAC (Slee et al., 2014). We 
anticipated that SAC override would result in aneuploidy as previously observed in other 
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cancer cell lines. While, we found that both knockdown and catalytic inhibition of TTK in 
the PANC-1 cell line increased aneuploidy, the HPAC cell line did not. Although this result 
was unexpected, previous reports have demonstrated heterogeneous response to TTK 
inhibition (Jemaà et al., 2013). The difference in response could perhaps be explained by the 
hypothesis that cells with extra chromosomes may have a greater requirement for SAC 
function (Storchová et al., 2006; Z Yang et al., 2008).  However, previous reported 
karyotypes show a modal number of 63 and 61 for the PANC-1 and HPAC cell lines 
respectively, suggesting that the level of aneuploidy does not account for this discrepancy 
(Lieber et al., 1975; Gower et al., 1994). Alternatively, the discrepancy could be attributed to 
differences in the genetic background of the two cell lines. Previous studies have shown that 
aneuploidy can stimulate a p53-dependent senescence-like growth arrest (Thompson and 
Compton, 2010; Li et al., 2010). PANC-1 cells have inactivating mutations in both alleles of 
p53, whereas HPAC cells have two wild-type p53 alleles (Deer et al., 2010). Mitotic errors 
resulting from TTK inhibition in HPAC cells may trigger p53 mediated growth arrest and 
prevent aneuploidy whereas PANC-1 lacking functional p53 continue to aberrantly divide.  
Further investigation in more PDAC cell lines with a wild-type p53 background will be 
required to determine whether TTK inhibition induces senescence-like phenotypes.  
Importantly, we found that both pharmacologic inhibition and knockdown of TTK 
severely decreased PDAC cell line proliferation and transformed growth. Our results are in 
agreement with prior reports in other tumor types where either pharmacologic inhibition or 
genetic knockdown of TTK resulted in a similar decrease in the growth of multiple cancer 
cell lines (Schmidt et al., 2005; Colombo et al., 2010; Kwiatkowski et al., 2010; Sliedrecht et 
al., 2010; Tardif et al., 2011; Daniel et al., 2011; Tannous et al., 2013; Jemaà et al., 2013; 
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Maire et al., 2013; Slee et al., 2013). However, a key observation from our study is that we 
observed greater impairment of proliferation with genetic knockdown compared to 
pharmacologic inhibition. These data suggest that non-kinase domains of TTK are important 
to support proliferation of aneuploid cells. Although poorly characterized, the much larger N-
terminus of TTK contains tandem tetratricopeptide repeats known to be important for protein 
binding (Thebault et al., 2012; S Lee et al., 2012; Nijenhuis et al., 2013). However, the 
binding partners are currently undetermined and future studies will be required to identify 
TTK binding partners and characterize how they contribute to adapting to aneuploidy. 
We also observed that 72 h of catalytic inhibition of TTK with AZ3146 did not 
induce apoptosis in the PANC-1 cell line whereas genetic knockdown of TTK did. In 
contrast to our results, Slee et al. found that pharmacologic inhibition of TTK with NMS-
P715 in PANC-1 cells did induce apoptosis (Slee et al., 2014). Differences in apoptotic 
induction may be due to non-TTK effects suggesting the need to further characterize these 
inhibitors. 
In agreement with previous studies, we clearly demonstrate that the catalytic activity 
of TTK is required for cancer cell line mitotic regulation and growth. However, the 
phosphorylation substrate(s) of TTK are less clear. In an attempt to characterize the 
molecular pathways downstream of TTK, we identified Usp16 as a novel phosphorylation 
substrate of TTK. Usp16 dependent deubiquitination of histone H2A is a prerequisite for 
chromosomal condensation (Kouzarides, 2007; Joo et al., 2007). We identified 3 TTK-
dependent phosphorylation sites on Usp16: S415, S552, and T554. Point mutations in Usp16 
(S415E, S552E, T554E) exhibited enhanced degradation compared to wild-type Usp16. We 
propose that phosphorylation and subsequent degradation of Usp16 may represent another 
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mechanism whereby TTK regulates genome stability by preventing chromosomal 
condensation and thus allowing more time to correct for errors that accumulated during DNA 
replication.  
The high levels of chromosomal instability that exists in PDAC present a window that 
may be exploited for therapy. Our results demonstrate that SAC inactivation through 
inhibition of the upstream activator TTK decreases the ability of PDAC to adapt and support 
the growth of aneuploid cells. TTK inhibition has previously been shown to enhance 
chromosomal instability and sensitivity of cancer cell lines when combined with the 
microtubule targeting drugs vincristine or taxol (Janssen et al., 2009; Tannous et al., 2013; 
Jemaà et al., 2013). Consistent with this idea, the microtubule targeting nab-paclitaxel in 
combination with gemcitabine was approved for PDAC therapy (Hoff et al., 2014). Future 
studies will be required to determine whether TTK inhibition sensitizes PDAC cells to nab-
paclitaxel. Altogether our results support continued study of the molecular mechanism that 
allow PDAC to adapt to chromosomal instability.
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CHAPTER IV 
Conclusions and Future Directions 
 
  In this dissertation I investigated the role of aberrant gene expression as a diagnostic 
marker and the therapeutic value of the gene products of an aberrantly-expressed gene in 
PDAC. Through the analysis of genome-wide gene expression profiles from PDAC patients, 
I have been able to identify a gene signature that can stratify patients into a high- and low-
risk groups associated with overall survival. In addition, I identified and characterized the 
functional role of overexpression of the protein kinase TTK in PDAC oncogenesis.  
  Three main observations arise from my studies: 1) The impact of gene expression 
signatures for diagnostic and prognostic evaluation of PDAC. 2) The therapeutic value of 
TTK in PDAC. 3) The identification of Usp16 as a phosphorylation substrate of TTK. Future 
studies are required to further understand the clinical relevance of these findings. 
Diagnostic gene expression for PDAC 
 One reason behind the high mortality rate of pancreatic cancer is the lack of selective 
and sensitive diagnostic tools for early detection. It is now accepted that there are three main 
precursor lesions: IPMN, MCN, and PanIN. While differences in morphological features and 
clinical outcome exist, each of these three precursor lesions can, through a multistep process, 
develop into invasive PDAC. Early detection of these lesions remains a challenge, yet 
development of diagnostic tools to detect tumors before the disease becomes invasive is 
necessary to allow for potentially curative surgical resection. The genetic progression of each 
of these lesions is also unique, yet some common genetic events, such as activating mutations 
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in KRAS and inactivating mutations of p53, and loss of p16ink4a, have been observed in each 
of the precursor lesions (Hezel et al., 2006; Smith et al., 2012). This pattern of common 
mutations suggests that, in part, similar signaling pathways are deregulated and may 
contribute to oncogenesis. Comparison of gene expression profiles of PanIN, MCN, and 
IPMN precursor lesions may help identify these pathways and provide novel insight into the 
development of PDAC. Identification of gene expression changes of secreted proteins may 
help identify potential early biomarkers of disease. Although overexpression or loss of 
mRNA that encodes for secreted proteins may be identified, extensive confirmation would be 
required before hits could be classified as biomarkers. 
Gene expression signatures and subtypes of disease    
  Whole-exome and genome sequencing have demonstrated that PDAC is a 
heterogeneous disease with diverse molecular subtypes (MH Jones et al., 2005; Biankin et 
al., 2012; Cowley et al., 2013). As previously seen with breast cancer (Parker et al., 2009), 
identification of the intrinsic molecular subtypes would impact clinical practices by helping 
asses risk for surgical procedures, therapy choice based on chemoresistance profiles, and 
identification of novel therapeutic targets. Therefore, it is vital that the molecular 
determinants of PDAC be defined. In this dissertation I present the first study to validate a 
prognostic gene signature for PDAC. It is important to note that this signature was developed 
by studying the molecular differences between nonmetastatic and metastatic primary tumors, 
suggesting that subtypes can be identified based on intrinsic tumor biology. Collisson et al. 
have since used consensus clustering of gene expression data to identify three molecular 
subtypes of PDAC: classical, quasimesenchymal, and exocrine-like. However, analysis of 
human and mouse PDAC cell lines failed to identify all three subtypes, suggesting that future 
work is needed to validate and potentially expand the subtypes of PDAC. It would be 
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interesting to perform consensus clustering on the TCGA and ICGC pancreatic cancer gene 
expression data set and compare any subtypes identified.  
  As subtypes of PDAC are identified, it will be necessary to perform extensive 
characterization of each subtype. Understanding the subtype-specific morphology, pathology, 
and clinical associations will be required to identify subtype-specific dependencies that can 
be targeted for therapy. Jones et al. identified 12 pathways and process whose component 
genes were genetically altered in PDAC (S Jones et al., 2008).  A similar analysis of gene 
expression data would complement the mutational analysis, identifying potential nodes for 
therapeutic intervention.    
Therapeutic value of TTK for PDAC 
  Another observation that arose from my studies is the importance of TTK in PDAC 
growth. Based on the in vitro work we hypothesize that TTK is important for in vivo PDAC 
tumorigenesis. To evaluate this hypothesis it would be necessary to study the effect of TTK 
inhibition in genetically engineered mouse model. The KrasLSL.G12D/+; p53R172H/+; 
PdxCretg/+ mouse model (KPC) faithfully recapitulates many of the characteristics of human 
PDAC including morphology, stromal desmoplasia, and metastasis (Westphalen and Olive, 
2012). To study the affect of TTK expression I propose to create a mouse model in the KPC 
mouse that also has a knockout of TTK. In zebra fish, inactivating mutations in the TTK 
orthologous gene nightcap, was embryonic lethal (Poss et al., 2002). Additionally, 
homozygous deletions of SAC components in mice are also embryonic lethal (Foijer et al., 
2008). Furthermore, complete checkpoint inhibition has been shown to have adverse effects 
on non-transformed immortalized breast cancer cell lines (Kwiatkowski et al., 2010; Maire et 
al., 2013), suggesting that in addition to pancreas specific depletion, knockdown may also 
need to be inducible to allow for proper organ development. Doxycycline-inducible tissue 
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specific knockdown has previously been demonstrated in the pancreas (Collins et al., 2012; 
Ying et al., 2012). A key benefit of this model is that protein knockdown can be depleted in 
an established tumor, allowing characterization of TTK expression for tumor maintenance.   
Based on my cell culture studies, I anticipate that TTK depletion in this setting will exhibit 
an increase in cell cycle defects resulting in impaired tumor growth.  
  Standard therapeutic intervention of protein kinases is accomplished by 
pharmacologic inhibition of the kinase activity. Since TTK is a larger protein (~97 kDa) with 
previously determined non-kinase domain sequences, it is possible that non-kinase functions 
of TTK also contribute to PDAC growth. To determine whether abolishing catalytic function 
of TTK alone decreases tumor growth I would create a conditional knock-in mouse model. In 
the KPC background I would replace the wild-type TTK gene with a mutant TTK with a 
catalytic domain mutation (D664A) previously shown to abolish TTK kinase activity (L 
Zhang et al., 2013).  
  Clinical efficacy of signal transduction inhibitors, in particular protein kinase 
inhibitors, has been hampered by emergence of cells resistant to the inhibitor.  Resistance 
may arise as a consequence of pharmacologic inhibition. Cells can become resistant by 
activation of alternative pathways to reactivate a node downstream of inhibitor’s target, and 
is an example of acquired resistance. In contrast, some tumors display intrinsic resistance. 
Intrinsic resistance occurs when cells within the tumor are inherently resistant to therapy 
before treatment begins. Initial clinical efficacy is observed with inhibitor treatment, as the 
sensitive tumor cells are eliminated and tumor size is reduced. However, the intrinsically 
resistant cells are unaffected by the inhibitor and eventually leading to tumor recurrence.  
  Resistance to a TTK pharmacologic inhibitor is a likely scenario. Therefore future 
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studies are needed to anticipate possible mechanisms of resistance with the goal to identify 
molecular targets that can be used to make a more effective combination therapy. To identify 
intrinsic and acquired resistance mechanisms I would isolate PDAC cell line variants after 
prolonged treatment with a high dose of the TTK inhibitor AZ3146. Comparison of exome 
sequencing of sensitive (pre-treatment) and resistant variants would identify mutations 
associated with resistance. Functional analysis would be required to determine the 
mechanism of resistance.  
  Aberrant activation of compensatory signaling cascades is another resistance 
mechanism that occurs in cancer, often referred to as feedback or reprogramming. To 
investigate compensatory reprogramming of the kinome that results from TTK inhibition I 
would determine global chances in kinase activation using multiplexed inhibitor beads and 
mass spectrometry (MIB/MS) (Duncan et al., 2012). Comparison of kinase activity profiles 
of PDAC cell lines pre- and post-treatment with a TTK inhibitor may identify signal 
transduction pathways that become activated to compensate for loss of TTK catalytic 
activity. Once these pathways are identified, combination of kinase inhibitors that target TTK 
as well as the compensatory pathways will need to be evaluated in vitro and in vivo. 
Anticipating the mechanisms of resistance will hopefully decrease the rates of recurrence in 
PDAC patients. 
Previous studies have also suggested that combination therapies of anti-mitotic drugs 
with TTK inhibitors enhance sensitivity. A study of glioblastoma cell lines found that 
inhibition of TTK enhanced sensitivity to the microtubule targeting drug vincristine 
(Tannous et al., 2013). In addition, treatment of colorectal cancer cell lines with sub-lethal 
does of a TTK inhibitor (Mps-Bay1 or Mps-Bay2a) with paclitaxel demonstrated a 
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synergistic effect. siRNA mediated knockdown of TTK demonstrated similar synergy when 
combined with paclitaxel (Jemaà et al., 2013). Recently a microtubule-targeted drug nab-
paclitaxel in combination with gemcitabine was approved for PDAC therapy (Hoff et al., 
2014). Future studies will be required to determine if TTK inhibition could synergize with 
nab-paclitaxel to not only improve patient response, but also allow a lower dose of paclitaxel 
and reduce adverse side effects. 
TTK phosphorylation substrates   
  Previous studies have found the importance of TTK for  multiple functions in the cell 
including SAC activation, genotoxic stress response, centrosome duplication, cytokinesis, 
and meiosis, yet for the most part the molecular mechanism and phosphorylation substrates 
of TTK remain unclear (X Liu and Winey, 2012). Additional phosphorylation events may 
occur specifically in cancer due to aberrant TTK overexpression and mislocalization. Only 
recently have TTK substrates been identified, and the list is continually growing.  
  A more comprehensive portrait of TTK substrates is needed for elucidating the 
molecular roles of TTK in the cell as well as identifing markers of response to anti-TTK 
therapy. The canonical function of TTK in regulation of the SAC is conserved in many 
eukaryotes, suggesting that there may be conserved substrates. In this work we identified 410 
putative TTK phosphorylation substrates in humans through bioinformatics analysis. To 
identify conserved phosphorylation substrates of TTK that may function to maintain genome 
stability I would perform a similar bioinformatics interrogation of conserved TTK orthologs 
in mice (Esk), zebra fish (nightcap), drosophila (ALD) and xenopus (TTK) to determine 
putative substrates.  Hits could be determined by finding the homologous substrates that 
overlap between species. Validation and functional analysis of these hits would then be 
required in vitro and in vivo.  
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  In addition to a bioinformatics approach, TTK phosphorylation substrates can also be 
identified by detailed proteomic approaches. There are nine available pharmacologic 
inhibitors of TTK, with varying selectivity for TTK. To identify phosphorylation substrates 
of TTK I would compare phosphorylation event changes identified by mass spectrometry of 
cells treated with TTK inhibitors. By identifying the proteins with decreased phosphorylation 
following treatment with multiple inhibitors I will limit identification of false positive 
substrates due to off-target inhibitor activity. These unbiased approaches will provide a 
strong basis for the continued studies and TTK biology and identify markers of response to 
anti-TTK therapy.  
Usp16 substrates and regulation 
  Proper chromosome dynamics during mitosis require TTK expression and function 
and inhibition of TTK promotes genome instability. My identification of Usp16 as a TTK 
phosphorylation substrate adds new dimensions to TTK signaling. Usp16 is a 
deubiquitinating enzymes whose best known function is deubiquitinating histone H2A to 
allow phosphorylation of serine 10 on histone H3 and trigger chromosomal condensation 
(Joo et al., 2007). Based on my studies here, inhibition of TTK causes stabilization of Usp16 
protein. Overexpression of Usp16 has previously been identified in Down syndrome where 
Usp16 is amplified and reduces self-renewal of hematopoietic stem cells, reduces the 
expansion of mammary epithelial cells, and accelerated senescence (Adorno et al., 2013), yet 
the molecular biology that mediate these phenotypes are unknown. To better understand how 
increased Usp16 mediates these functions it is necessary to conduct future studies to identify 
the deubiquitination substrates of Usp16.  
  In addition to the three TTK-dependent sites of phosphorylation on Usp16 our mass 
spectrometry approach also identified sites of phosphorylation that were not altered with 
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TTK inhibition in PDAC cell lines. In order to gain a better understanding of Usp16 biology 
in PDAC it will be necessary to identify the kinases that mediate these functions but also 
elucidate the effect of the remaining phosphorylation events on activity, localization, and 
substrate specificity. 
Summary 
 PDAC remains a lethal disease and only incremental improvement in therapy has 
been made. Through analysis of aberrant gene expression in PDAC we sought to translate the 
molecular biology of PDAC into clinically relevant diagnostic and therapeutic tools. In 
aggregate, our studies found two roles of aberrant gene expression in PDAC: 1) as a 
diagnostic tool to aid in making decisions about patient therapy and 2) as a tool to identify 
therapeutic targets.  
Future studies will be required to identify molecular subtypes associated with drug 
resistance and patient survival. In addition, future studies are required to validate the role of 
TTK in PDAC therapy, anticipate mechanisms of resistance, and improve our understanding 
of TTK biology by identifying and characterizing TTK phosphorylation and Usp16 
ubiquitination substrates.  
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